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9ABBREVIATIONS
AICD   activation-induced cell death
ANOVA  analysis of variance
AP-1   activator protein 1
APC   antigen-presenting cell
ADP   adenosine diphosphate
ATP   adenosine triphosphate
BMDM   bone marrow-derived macrophages
CBP   CREB-binding protein
CCL   CC chemokine ligand
CD   cluster of differentiation
CDK   cyclin-dependent kinase
CM-H2DCFDA		 chloromethyl-2’,7’-dichlorodihidrofluorescein	diacetate	acetyl	ester
ConA   concavalin A
CoQ   coenzyme Q (ubiquinone)
CRAC   calcium release-activated channel
CREB   cAMP response element-binding protein
Ctrl   control
CXCL   CXC chemokine ligand
Cyt c   cytochrome c
DC   dendritic cell
DNA   deoxyribonucleic acid
DPI   diphenyleneiodonium
e-   electron
EDTA   ethylenediaminetetraacetic acid
EGF   epidermal growth factor
Egr2   early growth response 2
EMSA   electromobility shift assay
ERK   extracellular signal-regulated kinase
F4/80   EGF-like module-containing mucin-like hormone receptor-like 1
FAD	 	 	 flavin	adenine	dinucleotide
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FADD   Fas-associated death domain
FADH2		 	 flavin	adenine	dinucleotide	(hydroquinone	form)
FasL   Fas ligand
FBS   fetal bovine serum
GADD   growth arrest and DNA damage
GM-CSF  granulocyte-macrophage colony-stimulating factor
H+   hydrogen ion
H2O   water
H2O2   hydrogen peroxide
HIF   hypoxia inducible factor
HRP   horseradish peroxidase
IFN   interferon
IFNAR   IFN-a/b receptor
Ig   immunoglobulin
IkB    inhibitor of kB 
IKK   IkB kinase
IL   interleukin
iNOS   inducible nitric oxide synthase
i.p.   intraperitoneal
IRAK   IL-1 receptor-associated kinase
IRF3   IFN-regulatory factor 3
IS   immunological synapse
Jak2   Janus kinase 2
JNK   c-Jun N-terminal kinase
Lck	 	 	 lymphocyte-specific	protein	tyrosine	kinase
lpr   lymphoproliferation
LPS   lipopolysaccharide
M1   classically activated macrophage
M2   alternatively activated macrophage
MAPK   mitogen-activated protein kinase
MHC   major histocompatibility complex
mRNA   messenger RNA
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mROS   mitochondrial ROS
MyD88  myeloid differentiation primary response protein 88
NADH   nicotinamide adenine dinucleotide (reduced form)
NADPH  nicotinamide adenine dinucleotide phosphate (reduced form)
NFAT   nuclear factor of activated T cells
NF-kB   nuclear factor kappa-light-chain-enhancer of activated B cells
NK   natural killer
Nrf2   nuclear factor erythroid 2-related factor 2
O2   molecular oxygen
O2-   superoxide
OH-   hydroxyl radical
OVA   ovalbumin
PBS   phosphate-buffered saline
PCNA   proliferating cell nuclear antigen
Pi   inorganic phosphate
PI   propidium iodide
RNA   ribonucleic acid
ROS   reactive oxygen species
RT-PCR  reverse transcription polymerase chain reaction
SD   standard deviation
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel elecrtophoresis
SEM   standard error of the mean
SHIP   src homology 2-containing inositol-5’-phosphatase
siRNA   small interfering RNA
SLE   systemic lupus erythematosus
SOCS1  suppressor of cytokine signaling 1
SOD   superoxide dismutase
STAT   signal transducer and activator of transcription
TAK1   TGF-b-activated kinase 1
TBE   tris borate EDTA
TCA   tricarboxylic acid
TCR   T cell receptor
12
tg   transgenic
TGF   transforming growth factor
Th   T helper
TIR   Toll/interleukin-1 receptor
TLR   Toll-like receptor
TNF   tumor necrosis factor
Tol   tolerized
TRAF6  TNF receptor-associated factor 6
TRAPS  tumor necrosis factor receptor-associated periodic syndrome
TRIF   TIR-domain-containing adaptor inducing IFN-b
Treg   regulatory T cell
Tyk2   Tyrosine kinase 2
WT   wild type
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ABSTRACT
Proinflammatory	 and	 anti-inflammatory	 immune	 reactions	 must	 be	 regulated	 precisely	 to	 maintain	
balance in the immune system. Excessive activation can result in hypersensitivity diseases such as 
autoimmunity or septic shock, leading to multiple organ dysfunction syndrome and death. Excessive anti-
inflammatory	activity	is	also	harmful,	as	it	can	lock	monocytes	and	macrophages	into	an	unresponsive	
state. Here we identify a role for p21 as a negative regulator of activated T cells and macrophages, 
which is independent of the previously known p21 function as a cell cycle inhibitor. Our data show that 
p21 controls T cell activation and IFN-g production through negative regulation of mitochondrial reactive 
oxygen species (mROS) production. When we overexpressed p21 in T cells of lpr mice, we were able 
to reduce T cell production of IFN-g, which led to amelioration of lupus-like disease in these mice. 
Further, we show that p21 negatively regulates LPS (lipopolysaccharide)-induced mROS production in 
macrophages. In the absence of p21, LPS-activated macrophages showed strong NFkB activation and 
increased IFN-b	secretion.	As	a	consequence,	p21-deficient	macrophages	showed	impaired	ability	to	
reprogram	their	proinflammatory	status	to	immunosuppression,	known	as	LPS	tolerance.	Our	findings	
point to a role for p21 in regulating the balance between active p65/p50 and inhibitory p50/p50 NF-kB 
complexes during LPS tolerance in macrophages. Finally, we show that p21 is an important component 
of macrophage reprogramming in human monocytes, with implications in sepsis, and thus demonstrate 
the	biological	significance	of	our	data.
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Immune response: balancing activation 
and deactivation
To establish an infection, a pathogen must 
first	 overcome	 epithelial	 barriers,	 such	 as	
the skin and mucus-lined body cavities. Any 
organism	 that	breaks	 through	 this	first	barrier	
encounters the next two levels of defense: the 
innate and adaptive immune systems. Infection 
by	a	pathogen	triggers	an	acute	 inflammatory	
response in which cells and molecules of the 
immune system move into the affected site. 
Substances released by the pathogen and 
from damaged tissue increase local vascular 
permeability and upregulate the expression 
of adhesion molecules on the vascular 
endothelium, attracting circulating cells to the 
infection site.
Neutrophils	are	the	first	cells	that	accumulate	
at the infection site, where they phagocytose the 
microbe coated with proteins of the complement 
system. Monocytes and macrophages are 
recruited to the site shortly after neutrophils, 
and persist for long periods at sites of chronic 
inflammation	and	infection.	They	produce	nitric	
oxide as a major mechanism for killing bacteria, 
as well as large amounts of cytokines such as 
IL12 and IL-18, giving them a regulatory role 
in adaptive immune responses. By taking up 
microbial antigens and presenting them in a 
complex with MHC, macrophages and dendritic 
cells also have key roles in adaptive immunity, 
serving as antigen-presenting cells.
T lymphocytes can be divided into different 
subpopulations with distinct functions. CD4+ T 
helper cells (Th) support the functions of other 
immune cells, such as B cells (which produce 
antibodies), macrophages, and T cells. CD8+ 
cytotoxic T cells kill cells that express foreign 
antigens, such as virus-infected cells or tumor 
cells. Naïve CD4+ T cells can differentiate into a 
variety of subsets, including Th1, Th2, Th17 and 
regulatory T cells (Treg). These subsets differ in 
the cytokines they produce and in their functions 
in host defense. Th1 cells secrete high levels of 
IFN-g and mediate defense against intracellular 
microbes. Th2 cells secrete high IL-4, IL-5 and 
IL-13 levels, and mediate defense against 
helminths. Th17 cells produce IL-17 and IL-22 
and defend against extracellular bacteria and 
fungi. Treg cells suppress immune responses 
and have an important function in preventing 
immune reactions against self-antigens.
After the pathogen is eliminated, the 
majority of effector lymphocytes die by 
apoptosis, thus returning the immune system 
to homeostasis. Imbalance between the 
effector mechanisms of immune responses 
and the control mechanisms that serve to 
limit such responses, lead to development of 
hypersensitivity disease such as allergic and 
autoimmune disorders. For example, after 
repeated exposure to an antigen, Th1 cells 
secrete IFN-g, which is responsible for many 
of the manifestations of autoimmune disease. 
IFN-g-activated macrophages secrete more 
cytokines,	 which	 promote	 inflammation,	 and	
produce more IL-12, thereby amplifying Th1 
responses. Sustained activation thus results 
in	 continued	 inflammation	 and	 tissue	 injury.	
Furthermore, excessive activation can result 
in septic shock, multiple organ dysfunction 
syndrome, and death. In contrast, excess 
anti-inflammatory	 activity	 is	 also	 harmful	 and	
could lock monocytes and macrophages in an 
unresponsive	state.	Proinflammatory	and	anti-
inflammatory	immune	reactions	must	therefore	
INTRODUCTION
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be precisely regulated to maintain immune 
system balance.
p21(WAF1/Cip1): far beyond cell cycle 
regulation
p21 (also known as p21WAF1/Cip1), a small 
165-amino-acid	 protein,	 was	 the	 first	 cyclin-
dependent kinase (CDK) inhibitor to be 
identified	 (Harper	 et	 al.,	 1993).	 p21	 was	 first	
described as a mediator of p53-induced G1 
arrest in response to DNA damage (Deng et 
al., 1995; Brugarolas et al., 1995; el-Deiry et 
al., 1993), as it halts DNA replication until errors 
are	fixed.	Today,	we	know	that	p21	is	involved	
in a far more complex network of interactions, 
thus affecting a plethora of biological functions 
and mechanisms in addition to cell cycle control 
(Scheme 1).
Non-overlapping structural domains of p21 
are responsible for interacting with two targets 
essential for cell cycle progression. Through its 
N-terminal	 domain,	 p21	 interacts	 specifically	
with the cyclin-CDK complex, thus preventing 
phosphorylation of the retinoblastoma protein 
and the consequent expression of E2F-
dependent genes, necessary for cell cycle 
progression (Vidal and Koff, 2000). p21 can 
also inhibit DNA replication directly, through its 
interaction with PCNA (proliferating cell nuclear 
antigen) via its C-terminal domain (Li et al., 
1994; Chen et al., 1995). p21 participates in 
a number of other protein-protein interactions, 
which opens the possibility of yet-undiscovered 
functions of this molecule.
p21 associates with E2F and thus directly 
regulates gene expression independently of 
cyclin/CDK (Delavaine and La Thangue, 1999). 
Through its C-terminal domain, p21 can also 
bind to c-Myc and suppress c-Myc-dependent 
p21
DNA damage
Cell cycle
Cyclin
CDK PCNA
DNA synthesis
E2F c-Myc
p300
GADD45
Gene expression
Procaspase 3
Apoptosis
Nrf2
Oxidative stress
Dierentiation
Oxidative stress
SCHEME 1 | p21 modulates multiple biological functions. The ability of p21 to engage in complex network of 
protein-protein interactions provides a likely basis for novel biological functions yet to be discovered.
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gene expression (Kitaura et al., 2000). Besides 
these transcription factors, p21 can interact 
with transcription coactivators such as CBP 
or p300, and enhance their function (Perkins 
et al., 1997; Snowden et al., 2000). GADD45, 
another molecule involved in growth arrest 
and DNA stability, also associates directly with 
p21 (Smith et al., 1994; Kearsey et al., 1995). 
Since both GADD45 and p21 can associate 
with mitogen-activated protein kinase (MAPK)-
related proteins, it was proposed that p21 and 
GADD45 cooperate in control of apoptosis 
rather than growth arrest (Shim et al., 1996; 
Takekawa and Saito, 1998). In support of its 
role in inhibiting apoptosis, p21 can associate 
with procaspase 3 and block its cleavage and 
activation, which protects from Fas-induced 
apoptosis (Suzuki et al., 1998). Paradoxically, 
some studies indicate that p21 can also 
promote apoptosis (Hingorani et al., 2000; 
Fotedar et al., 1999). These contrasting views 
might be explained by considering that the p21 
effect on apoptosis could be dependent on 
cell type and post-translational modulations 
such as phosphorylation, which affects p21 
cytoplasmic localization (Child and Mann, 
2006), or ubiquitylation, which affects p21 
stability. Growth-inhibitory and pro-apoptotic 
p21 functions might thus be associated with its 
nuclear localization, whereas p21 anti-apoptotic 
activities might be linked to its cytoplasmic 
accumulation (Coqueret, 2003).
Besides cell cycle control and apoptosis, p21 
has a role in differentiation. In epithelial cells, 
p21 is downmodulated along the differentiation 
pathway; conversely, p21 overexpression in 
these cells inhibits differentiation, suggesting 
that p21 must be inactivated for the late 
stages of differentiation to occur (Gartel et 
al., 1996; Pontén et al., 1995). The role of 
p21 in differentiation is not linked to its effects 
on the cell cycle (Di Cunto et al., 1998), and 
it can be negative or positive depending on 
cell type and differentiation stage (Casini and 
Pelicci, 1999). Recent evidence suggests that 
p21 is important for restricting stem cell self-
renewal in keratinocyte and hematopoietic 
systems, and for promoting their irreversible 
commitment to differentiation (Cheng et al., 
2000; Topley et al., 1999). Absence of p21 
therefore leads to increased stem cell potential 
of keratinocytes, resulting in enhanced 
susceptibility to carcinogenesis (Topley et al., 
1999). In hematopoietic system, however, p21 
has a dual role: on the one hand, it inhibits stem 
cell proliferation, and on the other, it stimulates 
proliferation of progenitor cells (Cheng et al., 
2000).
p21 came into the spotlight as a tumor 
suppressor after its initial discovery as a potential 
mediator of p53 tumor suppressor activity 
(el-Deiry et al., 1993). Although many human 
cancers correlate with p21 downregulation, 
p21 loss-of-function mutations are extremely 
rare, which suggests that p21 itself is not a 
classical tumor suppressor (Shiohara et al., 
1994; McKenzie et al., 1997; Abbas and Dutta, 
2009). Additional in vivo evidence indicating 
that	 loss	 of	 p21	 is	 not	 sufficient	 to	 promote	
malignancy came from a study in p21-/- mice, 
which showed that these mice do not develop 
spontaneous tumors early in life, as described 
for	 mice	 deficient	 in	 other	 tumor	 suppressor	
genes (Martín-Caballero et al., 2001).
Finally, several studies proposed a role 
for p21 in regulating oxidative stress (Fan 
et al., 1997; Esposito et al., 1998). In the 
lung, hyperoxia induces p21 expression and 
protects mice from oxidative stress (O’Reilly 
et al., 2001). p21 was shown to mediate anti-
oxidant response through direct interaction 
with the transcription factor Nrf2 (Chen et al., 
2009). Based on this study, p21-mediated 
induction of Nrf2 signaling was proposed 
to	 be	 a	 first	 line	 of	 defense	 used	 to	 reduce	
ROS in low-stress conditions, whereas high 
oxidative stress would lead to p21-mediated 
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cell cycle arrest or apoptosis (Villeneuve et al., 
2009). In addition, p21-/- mice fed with a high 
fat diet showed severe atherosclerosis due 
to increased NADPH oxidase activity, arguing 
for the protective role of p21 against oxidative 
stress (Khanna, 2009).
p21 as a regulator of innate and adaptive 
immune responses
Rather than developing tumors, p21-/- mice 
unexpectedly show manifestations of autoim-
mune disease (Balomenos et al., 2000). p21 
deficiency	combined	with	mild	autoreactive	ge-
netic backgrounds such as 129/Sv × C57BL/6 
or	 Gadd45a-deficient	 mice	 show	 severe	 lu-
pus-like autoimmunity, including splenomegaly 
and lymphadenopathy, which leads to death 
(Balomenos et al., 2000; Salvador et al., 2002). 
In mice on the autoimmunity-resistant C57BL/6 
(B6)	 background,	 p21	 deficiency	 results	 in	
autoantibody production and mild, non-lethal 
glomerulonephritis, suggesting that full-blown 
lupus development requires p21 deletion as 
well as elements from the 129/Sv × C57BL/6 
background (Arias et al., 2007). The role of p21 
in suppressing autoimmunity was reinforced by 
study	of	Egr-2-deficient	mice,	which	show	p21	
downregulation in T cells and develop autoim-
munity (Zhu et al., 2008). Several p21 alleles 
are associated with the development of sys-
temic lupus erythematosus in humans (Kong 
et al., 2007). A peptidyl mimic of p21 inhibits 
progression of lupus-like syndrome in NZB × 
NZW mice (Goulvestre et al., 2005), suggest-
ing that p21 can serve as a target molecule for 
improvement of therapeutic strategies for au-
toimmune disease. Indeed, we found that p21 
overexpression in T cells reduces lupus-like 
disease in lpr mice (Daszkiewicz et al., 2015). 
In addition to autoimmunity, p21-/- mice 
show	 enhanced	 proinflammatory	 cytokine	
production and septic shock-induced death 
when challenged with bacterial LPS (Trakala 
et al., 2009; Scatizzi et al., 2009; Mavers et 
al., 2012). These reports, including the data 
from our laboratory, demonstrate a critical 
role for p21 in regulation of gene expression 
in macrophages, through negative regulation 
of NF-kB activation (Trakala et al., 2009). 
Due to uncontrolled macrophage activation, 
p21-/- mice also show enhanced development 
of	 experimental	 inflammatory	 arthritis,	 which	
can be suppressed by administration of a p21 
mimetic peptide (Mavers et al., 2012). p21 
thus negatively regulates the macrophage 
inflammatory	response,	and	might	be	of	use	for	
controlling sepsis in humans.
Loss of tolerance and (de)regulation of T 
cell activation, proliferation and apoptosis
During primary immune responses, mature 
T cells, characterized by a naïve phenotype 
(low CD44 and high CD62L expression) 
recognize	 a	 specific	 antigen	 and	 differentiate	
into highly activated effector cells, which 
proliferate massively to establish a rapid 
immune response (Sprent and Surh, 2011). 
After resolution of the primary response, the 
majority of effector cells undergo apoptosis, 
leaving a small population of memory cells 
(characterized by high CD44 expression) that 
revert to a resting state (McKinstry et al., 2010). 
The precise regulation of total cell number, the 
proportion of naïve and memory T cells, and 
the extent of memory T cell expansion ⎯known 
as T cell homeostasis⎯ basically relies on the 
balance between proliferation and apoptosis 
(Freitas and Rocha, 2000). Deregulation of 
any of these steps (activation, proliferation or 
apoptosis) leads to loss of self-tolerance and 
autoimmunity.
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One way to control autoreactive T cells 
is activation-induced cell death (AICD). 
Repetitive TCR engagement with self-antigens 
triggers AICD through a mechanism that 
involves Fas/Fas ligand (FasL) interaction and 
subsequent recruitment of the Fas-associated 
death domain (FADD) adaptor protein, which 
activates caspase-8 and triggers the apoptotic 
cascade (Walker and Abbas, 2002). MRL/
lpr and gld mice, which bear mutations in 
Fas and FasL respectively, show a lupus-like 
lymphoproliferative syndrome (Watanabe-
Fukunaga et al., 1992; Sobel et al., 1993). 
Although the apoptotic defect is easy to 
demonstrate	 in	Fas-deficient	T	cells	activated	
in vitro, whether this defect is responsible for 
the loss of self-tolerance and development 
of autoimmunity remains a mystery. The 
first	 evidence	 that	 defective	 apoptosis	 alone	
cannot account for T cell accumulation came 
from studies with mice that overexpress 
caspase-8 inhibitor in T cells (Smith et al., 
1996). T cells from these mice showed 
defective apoptosis in vitro, but the mice did 
not develop lymphadenopathy or autoimmune 
disease. This suggested that Fas might have 
another role in T cell homeostasis other than 
apoptosis regulation. An additional property of 
Fas emerged from studies showing that T cell 
subsets from lpr mice exhibit a hyperactivation 
state and hyperproliferate (Balomenos et 
al., 1997; Fortner and Budd, 2005; Gupta et 
al., 2008). Autoimmune lymphoproliferative 
syndrome patients, who bear a mutation in 
the Fas-encoding gene, similarly show T cell 
hyperproliferation and lymphadenopathy (Le 
Deist et al., 1996). Another property of lpr T 
cells is high production of IFN-g, a Th1 cytokine 
that modulates anti-DNA antibody production 
and disease development in several lupus 
models	 (Altman	 et	 al.,	 1981;	 Theofilopoulos	
et al., 2001). It is thus tempting to speculate 
that non-apoptotic Fas functions control lpr T 
cell proliferation and activation (Alderson et 
al., 1993; Kennedy et al., 1999; Bosque et al., 
2008).
T cell activation and proliferation are 
linked, and there are many examples that 
clearly associate T cell hyperactivation and 
hyperproliferation with loss of self-tolerance and 
autoimmunity (Jury et al., 2010; Okazaki and 
Honjo, 2006; Sharpe et al., 2007). Data from 
our laboratory provided evidence that T cell 
homeostasis, tolerance and lupus-like disease 
are very dependent on cell cycle regulation of 
effector/memory T cells (Scheme 2). Studies 
of p21-/- mice suggested that p21 controls the 
proliferation of effector/memory but not naïve T 
cells (Balomenos et al., 2000; Arias et al., 2007). 
Moreover, absence of p21 does not affect Fas/
FasL-mediated apoptosis (Arias et al., 2007). 
T cells nonetheless require p21 to control their 
expansion, revealing a homeostatic mechanism 
that controls memory T cell expansion through 
p21. This role for p21 is in accordance with 
the fact that hyperproliferating T cells from 
lupus patients express markedly reduced 
p21 levels (Tang et al., 2009). A recent study 
showed	that	T	cell-specific	p21	overexpression	
TCR
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p21
Proliferation
(CDK2)
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(NF-κB)
p21
Hyperproliferation
Hyperactivation
Autoimmunity
SCHEME 2 | p21 suppresses autoimmunity by 
regulating T cell homeostasis. Studies from our group 
identify p21 as a negative regulator of effector/memory T 
cell proliferation. However, independently of its cell-cycle 
inhibitor function, p21 regulates T cells activation, most 
likely through NF-kB (unpublished observations).
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reduces lupus-like disease in lpr mice by 
limiting effector/memory T cell activation and 
proliferation, without affecting the apoptosis 
defect in these mice (Daszkiewicz et al., 2015). 
This suggested that p21 has another function 
in regulating T cell activation, independent of 
its cell cycle inhibitor role (Scheme 2).
IL-12 and IL-18, two cytokines derived 
from antigen-presenting cells (APC; such 
as activated macrophages), stimulate Th1 
responses and IFN-g production (Trinchieri, 
1994; Okamura et al., 1998). Although IL-12 
induces Th1 differentiation directly, IL-18 acts 
as a co-activator rather than as an initiator for 
Th1 responses (Robinson et al., 1997). IL-12 
alone or IL-18 alone induce only trace amounts 
of IFN-g in T cells and there is a marked 
synergism of IL-12 and IL-18 in IFN-g induction 
(Nakahira et al., 2002). IL-12 and IL-18 
use different signaling pathways to activate 
IFN-g production (Scheme 3). IL-12 receptor 
stimulation induces tyrosine phosphorylation of 
the Janus family kinases Jak2 and Tyk2, which 
results in phosphorylation of STAT4 (signal 
transducer and activator of transcription 4) and 
its translocation to the nucleus (Bacon et al., 
1995). The IL-18 receptor signals through IRAK1 
(IL-1 receptor-associated kinase) and TRAF6, 
resulting in NF-kB activation (Robinson et al., 
1997). IFN-g secreted by Th1 cells or natural 
killer (NK) cells has an important role in both 
innate and adaptive immunity. It is intimately 
involved in the pathogenesis of several 
diseases such as septic shock and systemic 
lupus erythematosus (Farrar and Schreiber, 
1993;	 Boehm	 et	 al.,	 1997;	 Theofilopoulos	 et	
al., 2001).
Overall, the regulation of T cell activation, 
proliferation and apoptosis are fundamental 
for maintenance of T cell homeostasis, 
establishment of tolerance, and suppression 
of autoimmune disease. Since p21 controls T 
cell tolerance and protects from autoimmunity, 
deciphering the precise effect of p21 on the 
overall immune response will help to evaluate 
the potential of p21-related therapeutic 
approaches to disease.
Mitochondrial ROS regulate T cell 
activation
Correct activation of naïve T cells requires two 
signals received from the APC (Scheme 4). The 
first	signal	is	delivered	by	binding	of	a	specific	
antigen presented by major histocompatibility 
complex (MHC) molecules on the APC to the 
TCR/CD3 complex. The second signal, also 
referred to as a co-stimulatory signal, arises 
from CD28 stimulation with B7 ligand (CD80 
and CD86) expressed on an APC. These 
signals trigger the T cell activation program that 
initiates rapid proliferation and differentiation 
to effector subsets (Th1, Th2, Th17 or Treg), 
as dictated by the invading organism type and 
cytokine	signals	from	other	inflammatory	cells.	
IL-12 R
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SCHEME 3 | Synergy between IL-12 and IL-18 for IFN-g 
promoter activation. IL-12 receptor stimulation induces 
phosphorylation of Jak2 and Tyk2, which results in 
STAT4 activation and its translocation to the nucleus. IL-8 
receptor signals through IRAK1 and TRAF6 and results in 
activation of NF-kB. 
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Activation of naïve T cells initiates immediate 
formation of an organized immunological 
synapse (IS) (Qi et al., 2001) and Ca2+	 influx	
across the plasma membrane through opening 
of Ca2+ release-activated calcium (CRAC)/
Orai1 channels (Yeromin et al., 2006). Elevated 
Ca2+ levels in the cytoplasm trigger activation 
of transcription factors, including nuclear factor 
of activated T cells (NFAT), activator protein 
1 (AP-1), and nuclear factor of kappa light 
chain enhancer in B cells (NF-kB), to promote 
expression of proteins that drive T cell activation 
such as interleukin 2 (IL-2) (Smith-Garvin and 
Koretzky, 2009). Immune synapse formation 
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antigen-presenting	cell	(APC):	TCR/CD3	complex	activation	by	a	specific	antigen	presented	by	major	histocompatibility	
complex (MHC) molecules on the APC, and co-stimulatory signal coming from interaction of CD28 with a B7 ligand 
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induces rapid translocation of mitochondria 
to the immediate vicinity of the IS. In fact, 
Ca2+	 influx	 depends	 on	 coupling	 between	
mitochondria and the IS, since mitochondria 
uptake of Ca2+ reduces its local accumulation 
and prolongs Ca2+	entry,	which	allows	efficient	
production of cytokines for an extended period 
(Quintana et al., 2007).
Whereas quiescent cells only need 
metabolism to support housekeeping functions, 
proliferating cells must produce more ATP for 
enhanced activity and biosynthesis. When 
activated, T cells therefore switch from a low 
rate of glycolysis and oxidation of pyruvate, to 
a high glycolysis rate followed by lactic acid 
fermentation, similar to the Warburg effect 
described in tumor cells (Warburg, 1956). Ca2+ 
activates key mitochondrial enzymes directly, 
causing an increase in tricarboxylic acid (TCA) 
flux	 (Tarasov	 et	 al.,	 2012),	 which	 generates	
NADH and FADH2, electron donors for the 
electron transport chain. Activated T cells 
thus increase their mitochondrial respiration 
and ATP production, resulting in increased 
production of mitochondrial reactive oxygen 
species (mROS).
ROS have long been considered harmful 
metabolism by-products that damage cell lipids, 
proteins and nucleic acids (Finkel and Holbrook, 
2000). Over the last decade, it has become 
evident that ROS are also crucial participants 
in cell signaling. ROS are small oxygen-
containing molecules that are highly reactive 
due to unpaired electrons. The most common 
ROS include superoxide (O2
-), hydrogen 
peroxide (H2O2) and the hydroxyl radical 
(OH-). Mitochondrial oxidative phosphorylation 
is a major source of cellular ROS (Murphy, 
2009). The mitochondrial respiratory chain 
(which carries out oxidative phosphorylation) 
is	 composed	 of	 five	 multi-subunit	 protein	
complexes localized in the inner mitochondrial 
membrane (see Scheme 4). Electrons (e-) are 
donated to complex I from NADH or to complex 
II from FADH2, and are passed to coenzyme Q 
(CoQ, also known as ubiquinone), which then 
carries them to complex III. From complex III, 
electrons are passed on to cytochrome c (Cyt c) 
and then to complex IV, where they participate 
in forming water (H2O) from hydrogen ions 
(H+) and molecular oxygen (O2). This electron 
movement is coupled to H+ pumping across the 
inner mitochondrial membrane from the matrix 
to the intermembrane space, which generates 
an electrochemical gradient used by complex 
V (known as ATP synthase) to generate 
ATP from ADP and inorganic phosphate 
(Pi). During oxidative phosphorylation, 
approximately 1-2% of consumed oxygen is 
converted into superoxide when electrons leak 
prematurely from complex I, II and II of the 
electron transport chain and are transferred 
to molecular oxygen (Orrenius et al., 2007; 
Koopman et al., 2010). Superoxide can then 
cross the outer mitochondrial membrane via a 
voltage-dependent anion-selective channel, or 
be converted to H2O2 by superoxide dismutase 
(SOD) (Han et al., 2003). H2O2 can freely cross 
the mitochondrial membrane and either react 
with	 specific	 amino	 acids	 (thereby	 activating	
signaling molecules such as phosphatases, 
kinases or transcription factors), or can be 
converted to OH- (which damages nearby 
molecules) or to H2O and O2 (by a catalase or 
peroxidase).
A study using the mitochondrial complex 
I inhibitor rotenone showed that mROS is 
essential for correct T cell activation and IL-2 
production (Kaminski et al., 2010). This study 
suggested that complex I-derived mROS 
facilitate cytokine production by regulating AP-1 
and NF-kB. In another study using mice with 
a targeted mutation in a complex III subunit, 
it was demonstrated that mROS is needed 
for	 antigen-specific	T	 cell	 expansion	and	 IL-2	
production (Sena et al., 2013). The authors also 
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showed that Ca2+	influx	into	the	mitochondria	is	
necessary for mROS production.
The role of mitochondria in memory T cell 
generation has been studied mainly in CD8+ 
cells. CD8+ memory cells show increased 
mitochondrial numbers and spare respiratory 
capacity, which relies on fatty acid oxidation 
to generate ATP (van der Windt and Pearce, 
2012). TRAF6 (TNF receptor-associated factor 
6) regulates CD8+ memory cell formation by 
modulating fatty acid metabolism (Pearce et al., 
2009). Although there is mounting evidence that 
mitochondrial metabolism maintains memory 
T cell phenotype, it is not known whether 
mROS participate in the signaling necessary to 
establish the memory T cell phenotype.
In conclusion, mitochondria play a central 
role in the early signaling events that control T 
cell activation. Increased Ca2+	influx	maintained	
by the mitochondria at the immune synapse as 
well as mitochondrial ROS production, both 
induce activation of key transcription factors 
that regulate T cell function. Finally, the idea that 
mitochondrial metabolism is needed for T cell 
activation is further supported by observations 
that chronically activated T cells isolated from 
mouse models of lupus are dependent on 
mitochondrial metabolism, and peripheral 
blood lymphocytes from lupus patients have 
increased mitochondrial ROS production 
(Gergely et al., 2002; Wahl et al., 2010).
Macrophage activation and mitochondrial 
ROS
Monocytes and macrophages have essential 
functions in defense against pathogens and 
activation of adaptive immunity, as well as 
in	 initiation	 and	 resolution	 of	 inflammation	
(Gordon and Taylor, 2005; Lawrence and 
Natoli, 2011). In response to diverse microbial 
and environmental signals, macrophages can 
polarize into different phenotypes with distinct 
effector functions, of which two extremes are 
classically	activated	(inflammatory	or	M1)	and	
alternatively activated macrophages (anti-
inflammatory	 or	 M2)	 (Mosser	 and	 Edwards,	
2008; Biswas and Mantovani, 2010; Gordon 
and Martinez, 2010; Mills, 2012). Macrophage 
plasticity is not limited to M1 and M2, but 
includes intermediate states with distinct 
polarization levels imposed by functional 
circumstances, some of which are described 
as M2a, Mb and M2c (Mantovani et al., 2004; 
Edwards et al., 2006). M1 macrophages are 
generated in response to IFN-g (produced 
by T cells) or microbial LPS; they produce 
large	 amounts	 of	 proinflammatory	 cytokines	
and eliminate intracellular microorganisms 
and tumor cells (Mantovani et al., 2002; Sica 
and Mantovani, 2012). In contrast, different 
forms of M2 macrophages can be generated 
by various stimuli, such as IL-4, IL-13, 
IL-10, TGF-b, glucocorticoids or immune 
complexes; they are involved in resolution 
of	 inflammation	 and	 parasite	 clearance,	 and	
are	 also	 identified	 as	 resident	 macrophages	
(Mantovani et al., 2002; Gordon and Martinez, 
2010; Sica and Mantovani, 2012; Satoh et al., 
2013; Mills, 2012). Macrophage plasticity is 
a key characteristic for maintaining balance 
between M1 and M2 forms, as loss of optimal 
representation and/or appropriate recruitment 
can lead to harmful imbalance. Increased 
levels of M1 macrophages are associated with 
autoimmune	and	 inflammatory	diseases	 such	
as lupus and multiple sclerosis (Orme and 
Mohan, 2012; Shechter and Schwartz, 2013), 
while a predominant M2 phenotype promotes 
tumor growth and development of allergic 
asthma (Dasgupta and Keegan, 2012; Hao et 
al., 2012).
LPS (lipopolysaccharide), a glycolipid 
component of the outer membrane of Gram-
negative bacteria, is a major activating agent of 
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macrophages that acts through TLR4 (Toll-like 
receptor 4) (Scheme 5). After binding to LPS, 
TLR4	 induces	 production	 of	 proinflammatory	
cytokines and IFN-b in a MyD88 (myeloid 
differentiation primary-response protein 88) 
and TRIF (Toll/interleukin-1 receptor-domain-
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SCHEME 5 | Macrophage activation.	After	binding	to	LPS,	TLR4	induces	production	of	proinflammatory	cytokines	
and IFN-b in a MyD88- and TRIF- dependent manner. MyD88 recruits IRAK1, which associates with TRAF6, leading 
to activation of TAK1, which in turn activates two distinct pathways involving IKK complex and MAPK pathway. IKK 
activity results in IkB phosphorylation and its subsequent degradation, which releases NF-kB and allows its nuclear 
translocation	where	it	activates	inflammatory	cytokines,	such	as	TNF-a, as well as IFN-b. On the other hand, IFN-b 
expression can be induced by IRF3, which is activated through TRIF in an MyD88-independent pathway. Once secreted, 
IFN-b causes autocrine activation of the IFNAR complex, leading to STAT1 phosphorylation and subsequent induction 
of IFN-responsive genes (iNOS, CXCL11). Thus, IFN-b	sustains	M1	inflammatory	response	following	LPS	stimulation.	
The role of p21 in negative regulation NF-kB through IKK has been established (Trakala et al., 2009). However, the 
mechanism how p21 controls macrophage activation remains unexplained. 
29INTRODUCTION 29
containing adaptor protein inducing IFN-b) 
-dependent manner. MyD88 recruits IRAK1 (IL-1 
receptor-associated kinase 1), which associates 
with TRAF6 (TNF receptor-associated factor 
6), leading to activation of TAK1, which in 
turn activates two distinct pathways involving 
the IKK complex (inhibitor of kB kinase) and 
the MAPK (mitogen-activated protein kinase) 
pathway (Kawai and Akira, 2007). IKK activity 
results in IkB phosphorylation and subsequent 
degradation; this releases NF-kB and allows its 
translocation to the nucleus where it activates 
inflammatory	 cytokines	 such	 as	 TNF-a as 
well as IFN-b. IFN-b expression can also be 
induced by IRF3 (IFN-regulatory factor 3), 
which is activated through TRIF in an MyD88-
independent pathway (Kawai and Akira, 
2010). Once secreted, IFN-b causes autocrine 
activation of the IFNAR (IFN-a/b receptor) 
complex, leading to phosphorylation of STAT1 
(signal transducer and activator of transcription 
1) and subsequent induction of IFN-responsive 
genes (iNOS, CXCL11). IFN-b thus sustains 
the	M1	 inflammatory	 response	 following	 LPS	
stimulation.
ROS are essential components of 
macrophage phagocytic activity and are 
needed for destruction of intracellular bacteria. 
It is thought that macrophages generate 
ROS primarily via the phagosomal NADPH 
oxidase machinery (Lambeth, 2004). Several 
studies suggest that ROS generated during 
mitochondrial oxidative phosphorylation also 
contribute to macrophage bactericidal activity, 
implicating mitochondria as signaling organelles 
in innate immunity (Arsenijevic et al., 2000; 
Chandel et al., 2000, 2001; Rousset et al., 2006). 
After TLR4 activation, TRAF6 can translocate 
to mitochondria, where it interacts with proteins 
involved in the mitochondrial respiratory chain, 
leading to increased mitochondrial and cellular 
ROS generation (West et al., 2011a). Patients 
with tumor necrosis factor receptor-associated 
periodic syndrome (TRAPS) have heightened 
responsiveness to LPS due to increased 
production of mitochondrial ROS (mROS) 
(Bulua et al., 2011). There is considerable 
evidence that mROS induced by TLR4 
activation acts as an important component 
of this signaling pathway through redox-
sensitive activation of the IKK complex and 
NF-kB,	 leading	 to	 pro-inflammatory	 cytokine	
production (Bai et al., 2005; Gloire et al., 2006; 
West et al., 2011b).
In addition to lymphocyte abnormalities, 
aberrations in monocyte/macrophage 
functions have been recognized increasingly 
to contribute to induction and development of 
autoimmunity (Li et al., 2010). TLR activation 
and the production of type I interferons 
(IFN-a/b) were recently implicated in the 
onset of systemic lupus erythematosus 
(SLE)	 pathogenesis	 (Theofilopoulos,	 2012).	
IFN-b can be produced by several cell types 
including macrophages, in response to TLR 
engagement during viral or bacterial infection, 
or to endogenous stimuli such as self-nucleic 
acid-containing immune complexes and 
necrotic debris (Elkon and Stone, 2011). 
IFN-b release primes plasmacytoid dendritic 
cells to produce IFN-a, which is present in 
large amounts in lupus patient serum (Hooks 
et al., 1979). Interferons are thought to have 
a pathogenic role in autoimmunity and in 
particular	 in	SLE,	 supported	by	 the	 finding	of	
IFN-inducible genes in the peripheral blood 
gene	expression	profile	in	individuals	with	SLE	
(Rönnblom et al., 1991; Baechler et al., 2003; 
Santiago-Raber et al., 2003). Moreover, serum 
levels of chemokines related to IFN activity are 
elevated in SLE patients (Kong et al., 2009). 
In humans, IFN-g administration can induce 
SLE or autoantibody production (Graninger et 
al., 1991). Conversely, administration of anti-
IFN-g or -IFNa/b receptor (IFNAR) antibodies 
decreases the levels of IFN-inducible genes 
in patient peripheral blood and ameliorates 
the disease in mice predisposed to lupus-like 
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disease (Santiago-Raber et al., 2003; Baccala 
et al., 2012; Welcher et al., 2015).
Type I interferons have long been known as 
potent antiviral molecules, and a critical role 
has been elucidated for IFN in LPS-induced 
endotoxemia. IFN-b knockout and IFNAR-
deficient	 mice	 are	 more	 resistant	 to	 LPS-
induced shock than WT mice (Karaghiosoff et 
al., 2003; Mahieu et al., 2006). In fact, IFNs 
mediate TNF-a induction during septic shock 
(Huys et al., 2009). Blocking IFN as well as 
proinflammatory	 cytokines	 appears	 to	 be	 a	
possible therapeutic strategy in experimental 
endotoxemia and in sepsis patients (Mahieu 
and Libert, 2007). In animal models of sepsis, 
neutralization	 of	 proinflammatory	 cytokines,	
such as TNF-a and IL-1b, severely reduces 
mortality (Beutler et al., 1985), although clinical 
trials did not show such success in patients 
(Fisher et al., 1996). In contrast to animals, which 
die of septic shock within 72 hours, patients die 
much later due to opportunistic infections and 
inability	 to	produce	proinflammatory	cytokines	
in response to LPS. IFN-g treatment was 
therefore proposed as an immunostimulatory 
therapy to restore monocyte activation in 
patients	at	the	hypoinflammatory	stage	(Döcke	
et al., 1997).
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SCHEME 6 | TLR4 signaling during LPS tolerance.	This	figure	summarizes	the	importance	of	inhibitory	p50/p50	
NF-kB	homodimer	 for	 shutting	down	proinflammatory	gene	expression,	and	 the	possible	 involvement	of	 IFN-b in 
promoting	sustained	proinflammatory	activation	which	could	interfere	with	LPS	tolerance.			
31INTRODUCTION 31
Macrophage reprogramming during LPS 
tolerance and sepsis
After long or repeated exposure to 
LPS, macrophages undergo functional 
reprogramming; they downregulate their 
proinflammatory	 M1	 profile	 and	 acquire	 an	
M2 phenotype (Porta et al., 2009; Pena et al., 
2011) (Scheme 6). These cells, referred to as 
LPS- or endotoxin-tolerant macrophages, are 
hyporesponsive to subsequent LPS challenge 
and	 no	 longer	 produce	 proinflammatory	
mediators such as TNF-a, IFN-b and iNOS 
(inducible nitric oxide synthase) (Foster et al., 
2007; Piao et al., 2009). Consistent with their 
M2 phenotype, LPS-tolerant macrophages 
upregulate prototypical M2 genes such 
as arginase I, IL-10 and Th-2-associated 
chemokines like CCL2 (Porta et al., 2009; 
Cubillos-Zapata et al., 2014). These M2 cells 
might nevertheless show important features 
that render them distinct from typical M2 
macrophages (Pena et al., 2011).
The refractory state of human monocytes 
after induction of endotoxin tolerance is 
also known as hyporesponsiveness or an 
immunosuppressive state; it has raised 
scientific	 interest,	 as	 a	 similar	 state	 of	
monocyte deregulation is observed in sepsis 
patients (Cavaillon and Adib-Conquy, 2006; 
Pena et al., 2014; Shalova et al., 2015). 
Sepsis is a complex condition characterized by 
large	 amounts	 of	 circulating	 proinflammatory	
cytokines, caused by a decontrolled innate 
response following systemic bacterial infection 
(Angus	and	van	der	Poll,	2013).	Inflammatory	
cells subsequently enter a temporary state of 
hyporesponsiveness and become tolerant to 
further endotoxin challenge. Monocytes isolated 
from sepsis patients are thus characterized by 
low	 proinflammatory	 cytokine	 profiles	 when	
they are stimulated ex vivo with LPS (Escoll 
et al., 2003). Monocyte hyporesponsiveness 
in sepsis does not correspond to simple 
downregulation	 of	 proinflammatory	 cytokine	
production, but rather to a reprogrammed state 
with alternative functional activity (Escoll et 
al., 2003; Cavaillon and Adib-Conquy, 2006; 
Shalova et al., 2015). Immunosuppression in 
sepsis	 was	 first	 considered	 a	 compensatory	
mechanism	that	regulates	hyperinflammation	to	
alleviate the deleterious effects of septic shock 
(Biswas and Lopez-Collazo, 2009; López-
Collazo and Del Fresno, 2013). This anti-
inflammatory	 response	 correlates	 with	 sepsis	
progression and death, however, and might 
increase the risk of secondary infection (Angus 
and	van	der	Poll,	2013)	or	lead	to	influx	of	other	
inflammatory	cells	(Ariga	et	al.,	2014;	Pena	et	
al., 2014). In mice, septic shock can be induced 
by a single LPS delivery, which corresponds to 
an	 initial	 proinflammatory	 response	 in	 sepsis,	
whereas endotoxin tolerance induced by LPS 
priming and rechallenge drives macrophage 
immunosuppression (Berg et al., 1995; 
Wysocka et al., 2001) and can be used as a 
model to study hyporesponsiveness in sepsis 
(López-Collazo and Del Fresno, 2013).
One of the major characteristics of 
endotoxin tolerance is the downregulation of 
proinflammatory	 cytokines	 such	 as	 TNF-a 
and IFN-b (Biswas and Tergaonkar, 2007). 
TNF-a regulation depends on NF-kB activation 
through TLR4 stimulation (Scheme 6). Although 
diverse pathways have been considered for 
IFN-b regulation (Toshchakov et al., 2002; 
Akira and Takeda, 2004), data from p50-/- 
mouse macrophages after LPS activation have 
also linked IFN-b to the NF-kB pathway and 
p50-regulating activity (Porta et al., 2009). In 
addition, as it has an essential function during 
Gram-negative bacterial infection in humans, a 
role for IFN-b in the pathology of human sepsis 
is proposed (Dejager et al., 2013).
The mechanism that regulates macrophage 
reprogramming from M1 to M2 during endo-
toxin	 tolerance	 remains	 largely	 undefined.	
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Nevertheless, overexpression of certain neg-
ative regulators of the TLR4 pathway, includ-
ing IRAK-M (interleukin-1 receptor-associat-
ed kinase-M), A20 and SHIP (src homology 
2-containing inositol-5’-phosphatase) is as-
sociated with macrophage unresponsiveness 
(Kobayashi et al., 2002; Sly et al., 2004; Biswas 
and Lopez-Collazo, 2009; Xiong and Medve-
dev, 2011). The IRAK-M inducer HIF1a (hypox-
ia inducible factor-1a)	 was	 recently	 identified	
as a mediator of endotoxin tolerance in sepsis 
(Shalova et al., 2015). Accumulation of the p50 
NF-kB subunit and predominance of p50/p50 
over p65/p50 NF-kB levels are linked to mac-
rophage hyporesponsiveness (Ziegler-Heit-
brock, 2001; Adib-Conquy et al., 2000). p50 
lacks a transcription activation domain and, 
when bound as a homodimer to gene promot-
ers, it blocks binding of active p65/p50 NF-kB 
and thus inhibits gene expression (Carmody 
and Chen, 2007; Hayden and Ghosh, 2008). 
p50 deficiency	 leads	to	defective	macrophage	
tolerance and M1 to M2 polarization (Porta et 
al., 2009). NF-kB regulation is therefore a key 
event in orchestrating M1 vs. M2 responses in 
LPS-tolerant macrophages, while the mech-
anism that regulates this NF-kB-dependent 
plasticity during endotoxin tolerance remains 
to	be	defined.
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OBJECTIVES
As	a	small	molecule	able	to	participate	in	a	number	of	specific	protein-protein	interactions,	p21	
plays a critical role in the regulation of many biological functions, such as cell cycle, apoptosis, 
cell differentiation and senescence, oxidative stress, and gene expression (Dotto, 2000). Ever 
since	 the	 initial	 discovery	 that	 p21-deficient	 mice	 develop	 lupus-like	 autoimmune	 disease	
(Balomenos et al., 2000), our group has focused on deciphering the role of p21 in regulation 
of immune responses. It was shown that in absence of p21, T cells hyperproliferate, leading to 
break of tolerance (Balomenos et al., 2000). p21 does not affect naïve T cells, but exclusively 
regulates the proliferation of effector/memory T cells that survive AICD (Arias et al., 2007). We 
recently showed that this p21 property has a therapeutic effect, since transgenic overexpression 
of p21 in T cells of lupus-prone B6/lpr mice reduces proliferation and activation of autoreactive 
T cells and ameliorates the disease (Daszkiewicz et al., 2015). Several reports, including the 
data from our group, also showed a role for p21 in regulation of innate immunity. In the absence 
of p21, macrophages have increased NF-kB	activity	and	proinflammatory	cytokine	production	
in response to LPS, making p21-/- mice extremely sensitive to septic shock (Trakala et al., 2009; 
Scatizzi et al., 2009). These reports clearly link p21 with regulation of both innate and adaptive 
immune responses. The mechanism by which p21 regulates T cells and macrophages, as well as 
its impact in human patients, nonetheless remained unexplained.
We therefore established the following objectives for the present study:
1. To investigate whether the role of p21 in controlling effector/memory CD4+ T cell activation 
is physiologically relevant for autoimmunity.
2. To study whether p21 controls IFN-g production directly in effector/memory CD4+ T cells.
3. To obtain mechanistic insight into how p21 controls effector/memory CD4+ T cell activation 
and IFN-g production.
4. To analyze the role of p21 in TLR4-dependent macrophage activation.
5. To determine whether p21, as a negative regulator of TLR4 activation, affects macrophage 
reprogramming during LPS tolerance.
6. To evaluate the mechanism by which p21 regulates macrophage reprogramming during 
LPS tolerance.
7. To	verify	whether	our	findings	on	the	role	of	p21	in	macrophage	reprogramming	during	
LPS tolerance are relevant for human sepsis.
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Animals
Mice were kept in the barrier zone of our 
animal facility to avoid contact with pathogens. 
Six to eight weeks old female mice were used 
for all experiments. C57BL/6 (B6, or WT) mice 
were from Harlan Interfauna Ibérica; p21-/- mice 
were obtained as described previously (Trakala 
et al., 2009). C57BL/6-lpr (B6/lpr) mice were 
from Jackson Laboratories. In C57BL/6-lpr-
p21tg (B6/lpr-p21tg) mice, generated from 
C57BL/6-lpr and C57BL/6-p21tg (B6-p21tg) 
mice, transgenic expression was restricted to 
T cells by the proximal Lck promoter (Fotedar 
et al., 1999). C57BL/6-lpr-p21-/- (p21-/-/lpr) 
mice were generated from C57BL/6-lpr and 
C57BL/6-p21-/- mice. 
Allergic asthma
To	induce	allergic	asthma,	five	WT	and	p21-/- 
mice were sensitized by two i.p. injections of 
10 mg OVA in 200 ml alum at day 0 and day 
11, whereas control mice were sham-sensi-
tized only with alum. Then from day 19 to day 
24 mice were challenged each day for 20 min 
with aerosolized 1% OVA in PBS inhalation 
and	sacrificed	24	h	after	the	last	treatment	for	
histological	analysis	of	lung	inflammation.	Con-
trol mice were sham-sensitized only with alum 
and aerosol challenged with PBS. Blood was 
obtained by cardiac puncture and OVA-specif-
ic IgE in serum was determined by sandwich 
ELISA	 (Cayman	Chemical).	Lungs	were	fixed	
in paraformaldehide and tissue sections were 
stained with hematoxylin and eosin for the 
evaluation	of	the	inflammatory	infiltrate.			
Induction of LPS tolerance in vivo
Mice were injected i.p. with 30 mg of LPS 
(from E. coli 0127:B8), followed 16 h later by 
an i.v. injection of 150 mg of LPS. Survival 
was monitored for 72 h. At 2 h post-LPS 
rechallenge, peritoneal exudates were 
harvested and blood was collected by cardiac 
puncture. For the IFNAR blocking experiments, 
two groups of p21-/- mice (n = 9 per group) were 
injected i.p. with 300 mg of IFNAR1 monoclonal 
antibody (MAR1-5A3, BioXCell), or a control 
IgG antibody (BioXCell) 2 h before the LPS 
rechallenge.  
Serological analyisis
IFN-g levels in T cell-free supernatants were 
determined by FlowMetrix system (Luminex, 
Austin, TX).
We tested mouse blood serum and cell-
free culture supernatants by ELISA for TNF-a 
(PeproTech) and IFN-b (PBL Assay Science) 
levels. The cytokine levels in the culture 
supernatants from the human samples were 
determined using the cytometric bead array 
(CBA) Flex Set (BD Biosciences) following 
the manufacturer’s protocol. The data were 
collected and analyzed using a BD FACSCalibur 
flow	cytometer	(BD	Biosciences).
Flow cytometry
To determine memory phenotype and 
activation, T cells were stained with anti-CD4-
PeCy7, -CD44-APC, -CD62L-PE and -CD69-
FITC (Beckman Coulter) antibodies. 
Peritoneal exudates were stained with 
anti-F4/80-APC (eBioscience), -CD11b-PE-
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Cy7 (BioLegend), -I-Ab-FITC (Thermo Fisher 
Scientific)	 and	 -CD40-PE	 (BioLegend)	 and	
analyzed on a Gallios cytometer (Beckman 
Coulter). The data were analyzed with FlowJo 
software (Tristar).
Intracellular cytokine staining
For intracellular cytokine detection, lymph 
node T cells were stimulated (4 h) in medium 
with phorbol 12-myristate 13-acetate (PMA, 50 
ng/ml) and ionomycin (2 mg/ml). Alternatively, 
for in vitro experiments after primary activation 
and IL-2 expansion, cells were stimulated 
with IL-12 plus IL-18 for 24 h. Brefeldin A (1 ×, 
BioLegend) was added during the last 3 h of 
stimulation. Cells were stained with violet LIVE/
DEAD stain kit (Invitrogen) to exclude dead 
cells. After surface marker staining with anti-
CD4-PeCy7, -CD44-APC, -CD62L-PE, cells 
were	washed	with	PBS,	fixed	and	permeabilized	
with	 Citofix/Citoperm	 kit	 (BD	 Biosciences)	
and blocked with 1 ml of Fc-receptor blocking 
antibody (Beckman Coulter) for 15 min at 4°C. 
Cells were stained intracellularly with anti-
IFN-g-FITC (1/100 dilution, eBioscience) and 
analyzed on a Gallios cytometer (Beckman 
Coulter).
In LPS tolerance experiments, WT and 
p21-/- mice were i.v. injected with Brefeldin A 
(500 ml of 1 × Brefeldin A in PBS; BioLegend) 30 
min post-LPS rechallenge. After 3 h, peritoneal 
exudates were harvested and stained with violet 
LIVE/DEAD stain kit (Invitrogen) to exclude 
dead cells. After surface marker staining with 
anti-CD11bPECy7 (BioLegend) and -F4/80-
APC (eBioscience), cells were washed with 
PBS,	 fixed	 and	 permeabilized	 with	 Citofix/
Citoperm kit (BD Biosciences) and blocked 
with 1 ml of Fc-receptor blocking antibody 
(Beckman Coulter) for 15 min at 4°C. Cells 
were stained intracellularly with anti-TNF-a-PE 
(1/100 dilution, eBioscience) and analyzed on 
a Gallios cytometer (Beckman Coulter).
Cell culture 
Mouse CD4+	 spleen	 T	 cells	 were	 purified	
by Negative Isolation Kit (Dynal Biotech); 
>85%pure CD4+ T cells were obtained. 
Purified	naïve	T	cells	(106/ml) were stimulated 
in vitro with concavalin A (ConA, 1.5 mg/ml, 
Sigma) in medium containing 20 ng/ml human 
recombinant interleukin 2 (IL-2, PeproTech), 
or in medium conditioned with anti-CD28 
(PharMingen, 1 mg/ml) in wells coated with 
anti-CD3 (PharMingen, 1 mg/ml in PBS). After 
1 day, cells were washed and cultured in 
medium with 20 ng/ml IL-2 for 6 days, followed 
by restimulation with IL-2 in combination with 
either ConA, or anti-CD3/CD28, or IL-12 
(10 ng/ml) plus IL-18 (10 ng/ml). 
For macrophage cultures, peritoneal 
exudate cells (PEC) were harvested from B6/
lpr mice that were injected i.p. with 1 ml of 3% 
thioglycollate medium (Difco) 4 days before 
isolation. PEC were cultured for 2 h in RPMI 
1640 without FBS and non-adherent cells 
were removed by washing with PBS; adherent 
macrophages were cultured overnight in 
complete RPMI 1640 with 10% FBS. Cells 
were incubated for 20 h in the presence of 1:2 
diluted cell-free culture supernatants from B6/
lpr or B6/lpr-p21tg (collected 24 h after second 
ConA stimulation). Control cells were cultured 
in medium alone or stimulated for 20 h with 
IFN-g (100 or 50 U/ml, Sigma).
To induce tolerance, adherent peritoneal 
macrophages from WT and p21-/- mice were 
treated with LPS (100 ng/ml; E. coli 0127:B8; 
Sigma) for 20 h, washed with PBS, maintained 
in medium for 2 h and then restimulated with 
LPS (100 ng/ml) for 4 h (12). Control cells 
were tolerized with LPS (20 h), washed and 
maintained in the medium for 6 h, without LPS 
rechallenge. To induce LPS activation, cells 
were incubated in medium for 20 h, washed, 
left in medium for 2 h and stimulated with LPS 
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for 4 h. Unstimulated cells were maintained 
in medium throughout the entire experiment. 
IFN-b depletion assays were performed by 
incubating with anti-IFN-b antibody (7F-D3; 
Yamasa Corporation), or isotype control (Rat 
IgG1, Antigenix America) at a concentration of 
6.7 mg/ml. 
The monocytes were obtained from 
peripheral blood and purity was tested as 
previously described (Cubillos-Zapata et 
al., 2014). To establish endotoxin tolerance, 
monocytes were tolerized with 10 ng/ml LPS 
(16 h), washed with PBS and rechallenged 
with 10 ng/ml LPS for indicated time periods. 
The control cells were not tolerized and/or 
rechallenged with LPS.
Bone marrow differentiation
To obtain bone marrow-derived macrophages 
(BMDM), bone marrow was collected from WT 
and p21-/- mice and cultured in Petri dishes for 
7 days in DMEM containing 10 % FBS plus 
30% L929 conditioned medium. Medium was 
replenished on day 4 of the culture. On day 7, 
>95% pure CD11b+F4/80+ macrophages were 
used for experiments. 
To generate dendritic cells (DC), bone 
marrow progenitor cells from B6 mice were 
cultured with GM-CSF (20 ng/ml) obtained 
from supernatant of the melanoma tumor D5-
G6 cell line. Medium was replenished on day 
4 of the culture. At day 6, slightly adherent 
and non-adherent cells were collected with 
PBS/3mM EDTA, re-plated and incubated in 
the presence of GM-CSF (20 ng/ml) and IL-4 
(1 ng/ml) for 24 h. Next, DC were stimulated 
with 1 mg/ml LPS (O26:B6, Sigma) and 1 mM 
OVA peptide (323-339) for 20 h. Non-adherent 
cells	were	characterized	by	flow	cytometry	and	
>60% of CD11c+MHCII+CD86+ dendritic cells 
were obtained. 
OT-II CD4+ T cell stimulation
Purified	 naïve	 OT-II	 and	 p21-/- OT-II CD4+ 
T	 cells	 were	 stimulated	 with	 specific	 OVA	
peptide (Robertson et al., 2000) presented by 
dendritic cells (DCs) obtained from WT (B6) 
mice (T cell:DC cell ratio 10:1). After 24 h of 
primary stimulation, T cells were expanded 
in IL-2 for 6 days and restimulated with OVA-
loaded DCs for indicated times.
ROS measurements
Cells were incubated with MitoSOX Red (to 
measure mROS superoxide) or CM- H2DCFDA 
(to measure total cellular H2O2) (Invitrogen) at 
5 mM	final	 concentration	 in	complete	medium	
for 30 min at 37°C. Mitochondrial ROS inhibitor 
DPI (5 mM, Sigma) was added to cell culture 
1	h	before	 the	stimulus.	Median	fluorescence	
intensity	was	measured	by	flow	cytometry.	To	
control	 for	 baseline	 fluorescence,	 samples	
from each experiment were left unstimulated 
but stained according to the above procedure. 
Relative	fluorescence	was	calculated	by	dividing	
stimulated by unstimulated values. Error bars 
were generated by calculating standard error 
of the mean from triplicate samples. All ROS 
experiments shown are representative of three 
independent experiments. 
Cell cycle analysis
To analyze cell cycle, 1 × 106 cells were 
permeabilized with detergent, stained with PI 
according to the manufacturer’s instructions 
(DNA-Prep Reagent Kit, Beckman Coulter) for 
30	min	at	37°C,	and	analyzedby	flow	cytometry.
Real-Time PCR
Macrophage cultures were washed with ice-
cold PBS and total RNA was extracted with 
TRIzol (Sigma) according to the manufacturer’s 
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instructions.   Reverse transcription from 1 mg 
of RNA was performed using the cDNA kit 
(Appled Biosystems). Real-time PCR was 
performed using EvaGreen Master Mix (Solis 
BioDyne) and detected by the ABI PRISM 
7900HT (Applied Biosystems). Data were 
processed using SDS 2.4 software (Applied 
Biosystems). Results were normalized to the 
expression of the b-actin and presented as the 
fold induction with respect to the control cell 
population. Due to high IL-10 mRNA levels in 
unstimulated cells, results of IL-10 expression 
were normalized to unstimulated cells of 
each genotype to calculate the amplitude of 
the transcription response (“dynamic range”) 
(Karaghiosoff et al., 2003) after stimulation. 
The	products	were	amplified	using	primers	for	
p21, 5’-GCA GAT CCA CAG CGA TAT CC-3’ 
(forward) and 5’-CAA CTG CTC ACT GTC CAC 
GG-3’ (reverse); arginase I, 5’-CAC TCC CCT 
GAC AAC CAG CT-3’ (forward) and 5’-AAG 
GAC ACA GGT TGC CCA TG-3’ (reverse); 
YM1, 5’-ACT TTG ATG GCC TCA ACC TG-3’ 
(forward) and 5’-AAT GAT TCC TGC TCC TGT 
GG-3’ (reverse); CCL17, 5’-GGC CTT GGG 
TTT TCA CCA-3’ (forward) and 5’-CAG GGA 
TGC CAT CGT GTT TC-3’ (reverse); TNF-a 5’-
CTG TAG CCC ACG TCG TAG C-3’ (forward) 
and 5’-TTG AGA TCC ATG CCG TTG-3’ 
(reverse); IL-1b, 5’-TGG TGT GTG ACG TTC 
CCA TT-3’ (forward) and 5’-CAG CAC GAG 
GCT TTT TTG TTG-3’ (reverse); IFN-b, 5’-TCA 
GAA TGA GTG GTG GTT GC-3’ (forward) and 
5’-GAC CTT TCA AAT GCA GTA GAT TCA-3’ 
(reverse); iNOS, 5’-GCT GTG CTC CAT AGT 
TTC CAG-3’ (forward) and 5’-GGA CCA GCC 
AAA TCC AGT C-3’ (reverse); CXCL11, 5’-AAA 
GAC AGC GCC CCT-3’ (forward) and 5’-GGC 
TGC TGA GAT GAA CAG GAA-3’ (reverse); 
IL-10, 5’-CGG GAA GAC AAT AAC TG-3’ 
(forward) and 5’-CAT TTC CGA TAA GGC TTG 
G-3’ (reverse); IRAK-M, 5’-TGA GCA ACG 
GGA CGC TTT-3’ (forward) and 5’-GAT TCG 
AAC GTG CCA GGA A-3’ (reverse); b-actin, 5’-
GGC TGT ATT CCC CTC CAT CG-3’ (forward) 
and 5’-CCA GTT GGT AAC AAT GCC ATG 
T-3’ (reverse). All primers were synthesized, 
desalted,	and	purified	by	Sigma.
For human samples, RNA was isolated 
using the High Pure RNA Isolation Kit (Roche 
Diagnostics). The cDNA was obtained by 
reverse transcription of 1 mg RNA using the 
High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Real-time quantitative 
PCR was performed using the QuantiMix Easy 
SYG kit from Biotools. Results were normalized 
to the expression of b-actin, and the cDNA copy 
number for each gene was determined using a 
7-point standard curve, as described previously 
(Del Fresno et al., 2005). The products were 
amplified	using	primers	for	TNF-a, 5’-GCC TCT 
TCT CCT TCC TGA TCG T-3’ (forward) and 
5’-CTC GGC AAA GTC GAG ATA GTC G-3’ 
(reverse); CCL2, 5’-GAT CTC AGT GCA GAG 
GCT CG-3’ (forward) and 5’-ATT CTT GGG 
TTG TGG AGT GAG TGT TCA-3’ (reverse); 
p21, 5’-GAG GCC GGG ATG AGT TGG GAG 
GAG-3’ (forward) and 5’-CAG CCG GCG TTT 
GGA GTG GTA GAA-3’ (reverse); IFN-b, 5’-
CCT GGC TAA TGT CTA TCA TCA-3’ (forward) 
and 5’-GCA GTA CAT TAG CCA TCA GTC-3’ 
(reverse); b-actin, 5’-AAG AGC TAC GAG CTG 
CCT GAC G-3’ (forward) and 5’-TCC ACA TCT 
GCT GGA AGG TGG-3’ (reverse). The primers 
were	 synthesized,	 desalted	 and	 purified	 by	
Bonsai Biotech.
Western blot
Cultured T cells were washed with ice-cold 
PBS and lysed in a buffer containing 0.2% 
Nonidet P-40, 10 mM Tris-HCl [pH 7.5], 150 
mM NaCl, and 1 × protease and phosphatase 
inhibitor cocktail (Roche), for 20 min at 4°C. 
The lysates were centrifuged at 14,000 × g 
for 15 min; the supernatants were measured 
using the Bio-Rad protein assay and resolved 
in 12% SDS-PAGE (20 mg protein per 
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lane). Proteins were next transferred into a 
nitrocellulose membrane (75 min at 300 mA) 
and immunoblotted using antibodies against 
phospho-STAT4 (Cell Signaling), p21 (Santa 
Cruz Biotechnology) and actin (Sigma). HRP-
conjugated secondary antibodies (Dako) 
were used at 1:2,000 dilution for 1 h at room 
temperature. Blots were visualized using 
Western Lightning Plus-ECL (PerkinElmer).
Macrophage lysates (20 mg protein) were 
analyzed using antibodies against p21, p50, 
p65 (Santa Cruz Biotechnology), phospho-
STAT1 (Y701), phospho ERK, IkBa, phospho 
IRF3 (Cell Signaling), iNOS (Abcam), JNK 
(Invitrogen), actin (Sigma). 
EMSA
NF-kB double stranded consensus 
oligonucleotides (5’-AGT TGA GGG GAC 
TTT CCC AGG C-3’) were purchased from 
Promega; double stranded oligonucleotides 
corresponding to the PRDII domain of the IFN-b 
promoter (5’-GGG AAA TTC CGG GAA ATT 
CC-3’) and oligonucleotides with mutant NF-kB 
sites (5’-act AAA TTC CAC TAA ATT CC-3’) 
were purchased from Sigma. They were end-
labeled with [g32P]ATP (PerkinElmer) using the 
T4 polynucleotide kinase (Promega). Binding 
reactions were prepared using 5 mg of nuclear 
extract in a 25 ml reaction volume containing 
0.5 ng labeled oligonucleotide probe, 10 mM 
HEPES, 1 mM MgCl2, 35 mM NaCl, 0.5 mM 
EDTA, 0.5 mM DTT, 10% glycerol, 1 mg bovine 
serum albumin and 1.5 mg poly[d(I-C)] at room 
temperature for 30 min. For supershift analysis, 
1 mg of antibodies against p50 (D-17) or p65 
(F-6) NF-kB (Santa Cruz) were added to the 
reaction mixture at room temperature for 20 
min prior to the addition of radiolabelled probes. 
Binding reactions were resolved on a 4% non-
denaturing polyacrylamide gel at 300V for 1.5 h 
at 4°C in 0.5 × TBE. Gels were subsequently 
dried	 and	 exposed	 to	 X-ray	 film	 at	 -80°C.	
Densitometry was performed using Quantity 
One 4.6.6 software (Bio-Rad). Alternatively, 
gels were exposed to a phosphor screen and 
visualized on a Personal Molecular Imager 
(Bio-Rad) and similar data were obtained. 
Immunoprecipitation and CDK2 kinase 
assay
For immunoprecipitatin and CDK2 kinase 
assay (Trakala et al., 2009), cells were lysed 
in buffer containing 50 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 0.5% NP-40, protease inhibitor 
cocktail and phosphatase inhibitor cocktail 
(Roche). Protein lysates (200 mg) were mixed 
overnight at 4° C with 2 mg anti-CDK2 (M2, Santa 
Cruz) and incubated with pre-blocked protein 
G-Sepharose beads (25 ml, Invitrogen) for 
additional 2 h. Anti-CDK2 immunoprecipitates 
were then incubated with 20 ml kinase buffer 
(20 mM Tric-HCl (pH 8.0), 10 mM MgCl2, 1 mM 
EGTA, 1 mM dithiothreitol, 1 mM NaF, protease 
inhibitor cocktail and phosphatase inhibitor 
cocktail), supplemented with 5 mg histone H1 
(Roche), 0.5 mM ATP (Cell Signaling) and 
10 mCi [g-32P]ATP (3000 Ci/mmol; Perkin Elmer; 
30 min at 30° C). Phosphorylated histone H1 
was resolved by gel electrophoresis.   
Patients
We included 7 subjects with sepsis 
secondary to a urinary tract infection (clinical 
details in Table I) who were admitted to the 
Department of Internal Medicine Service at 
La Paz Hospital (Madrid, Spain). The patients 
met	 the	 consensus	 conference	 definition	 of	
sepsis (American College of Chest Physicians/
Society of Critical Care Medicine Consensus 
Conference:	 definitions	 for	 sepsis	 and	 organ	
failure and guidelines for the use of innovative 
therapies in sepsis., 1992) and sepsis was 
confirmed	 by	 blood	 cultures	 positive	 for	
Escherichia coli. Peripheral blood was collected 
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within	 24	 h	 of	 sepsis	 confirmation.	 Exclusion	
criteria included presence of malignancy or 
chronic	 inflammatory	 diseases,	 treatment	
with steroids or immunosuppressive drugs 
during the last month, hepatic failure (serum 
aspartate aminotransferase and/or alanine 
aminotransferase > 100 IU/L; prothrombin 
time < 60%; total bilirubin < 60 mmol/L), renal 
insufficiency	(plasma	creatinine	>	200	mmol/L),	
HIV/AIDS, hepatitis B or C, pregnancy and 
age > 80 years. Blood collected from healthy 
volunteers served as controls.   
Small interfering RNA
p21 (ID 1531) and the control small 
interfering RNAs (siRNAs) were designed 
and synthesized by Life Technologies. Human 
monocytes were transfected with siRNAs 
using the Amaxa Nucleofector system (Amaxa 
Biosystems).	 Briefly,	 1.5	 ×	 106 monocytes 
were nucleofected with 30 mM siRNA mixed 
with 100 ml nucleofection solution, according 
to the manufactrer’s instructions. The cells 
were then immediately transferred to a six-well 
culture	plate	(Costair)	in	a	final	volume	of	2	ml	
prewarmed RPMI 1640 media supplemented 
with 10% heat-inactivated FBS (Invitrogen). 
The nucleofected cells were cultured at 37°C 
with 5% CO2 for 1 h before the assays.      
Statistical analysis
Statistical	 significance	 was	 determined	
by one-way ANOVA, two-way ANOVA (with 
Bonferroni correction), unpaired two-tailed 
Student’s t test or Mann-Whitney U test, as 
indicated. Survival curves were generated 
using Kaplan-Meier method, and compared 
using log-rank test. The correlation analysis was 
assessed	using	Pearson	correlation	coefficient.	
All statistical analyses were conducted using 
Prism 6.0 software (GraphPad). *p<0.05; 
**p<0.01; ***p<0.001. 
Study approval
All animal experiments were designed in 
compliance with European Union directives 
and guidelines, and were approved by the 
Centro Nacional de Biotecnología Ethics 
Committee. We obtained informed consent 
from all participants. The study was performed 
in accordance with the Helsinki Declaration 
of 2000 and was approved by the “La Paz 
Hospital” Ethics Committee.
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Studies of p21-/- mice suggested that p21 
controls the proliferation of TCR-stimulated 
but not naïve T cells, leading to development 
of lupus-like autoimmune disease (Balomenos 
et al., 2000; Arias et al., 2007). These 
studies show that p21 does not affect Fas/
Fas ligand (FasL)-mediated apoptosis, and 
suggest that p21 regulates the proliferation 
of apoptosis-resistant effector/memory T 
cells.	 p21	 deficiency	 in	 autoimmunity-prone	
mice leads to severe lupus-like disease and 
death (Bygrave et al., 2004; Balomenos et al., 
2000; Salvador et al., 2002). To provide direct 
evidence that p21 controls autoreactive T cells, 
and to explore the therapeutic effect of p21 
in lupus autoimmunity, we generated B6/lpr 
mice (homozygous for the Faslpr mutation, on a 
C57BL/6 background) that express the human 
p21 transgene in T cells, under the control of 
the proximal Lck promoter (B6/lpr-p21tg mice) 
(Daszkiewicz et al., 2015). p21 overexpression 
inhibited B6/lpr DN T cell lymphadenopathy and 
decreased effector/memory T cell proliferation 
and autoimmune symptoms. Further analysis 
showed that p21 overexpression reduced 
not only the proliferation, but also the activity 
of effector/memory B6/lpr T cells as well as 
their IFN-g production. This result suggested 
that p21 has functions other than cell cycle 
inhibition in the control of T cell responses. Our 
first	objective	was	therefore	to	study	the	role	of	
p21 in effector/memory CD4+ T cell activation 
and IFN-g production.
T cell-directed p21 overexpression reduces 
effector/memory CD4+ T cell activation and 
IFN-g production in B6/lpr mice
To examine whether p21 overexpression 
affects the activation of effector/memory CD4+ T 
cells in B6/lpr-p21tg mice, we analyzed surface 
expression of CD69, a T cell activation marker 
associated with memory T cells (Schoenberger, 
2012). In accordance with the fact that the 
effector/memory T cell population in B6/lpr mice 
is hyperactivated, lymph node CD44hiCD62Lhi 
CD4+ B6/lpr T cells showed a marked increase 
(>4-fold) in CD69 expression compared to the 
equivalent B6 population (Figure 1A). In B6/
lpr-p21tg mice, p21 overexpression reduced 
CD69 levels in the effector CD44hiCD62Lhi 
population by ~50% (Figure 1A, upper panels), 
without affecting CD69 expression in memory 
CD44hiCD62Llo cells, which was similar in B6 
and B6/lpr mice (Figure 1B, upper panels). As a 
control, we used B6-p21tg mice, which showed 
no exogenous p21 effect on CD69 expression 
in B6 effector/memory T cells (Figure 1A and 
B, lower panels). These data indicate that p21 
overexpression reduces CD69 expression by 
hyperactivated effector B6/lpr T cells.
To test whether p21 overexpression had an 
effect on B6/lpr T cell function, we analyzed 
production of IFN-g, a key cytokine associated 
with disease development in lupus models 
(Balomenos et al., 1998). The proportion 
of IFN-g-producing cells was markedly 
increased in B6/lpr mice in both effector 
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CD44hiCD62Lhi and memory CD44hiCD62Llo 
T cells compared with equivalent populations 
in B6 mice (Figure 2A and B). In B6/lpr-
p21tg mice, p21 overexpression decreased 
the frequency of IFN-g+ cells in effector and 
memory T cell populations (Figure 2A and 
B, upper panels), with no effect on B6-p21tg 
T cells (Figure 2A and B, lower panels). As 
memory T cell characterization is complex, 
we also analyzed another memory CD4+ T 
cell	 population	 defined	 as	 small	CD44hi cells, 
selected	 by	 forward	 scatter	 in	 flow	 cytometry	
(Rogers	et	al.,	2000).	Once	again,	we	confirmed	
that p21 overexpression reduced memory 
T cell accumulation and IFN-g production in 
B6/lpr-p21tg mice (Figure 2C, left panels), 
without affecting the equivalent B6-p21tg T cell 
population (Figure 2C, right panels). These 
data show that p21 overexpression reduces 
not only effector/memory T cell generation in 
B6/lpr mice, but also their activation and IFN-g 
production.
p21 overexpression reduces IFN-g 
production in B6/lpr T cells after repeated 
in vitro stimulation
After in vitro TCR stimulation and IL-2 
expansion, secondary TCR stimulation leads 
to activation of the Fas/FasL system and 
apoptosis (AICD, activation-induced cell 
death). lpr T cells nonetheless have defective 
AICD and hyperproliferate when restimulated 
in vitro (Singer et al., 1994). In addition to 
reducing B6/lpr-p21tg T cell hyperproliferation 
after secondary TCR stimulation, p21 
overexpression also reduced conversion of 
memory to effector cells, suggesting that the 
p21 transgene negatively regulates B6/lpr 
T cell activation (Daszkiewicz et al., 2015). To 
corroborate these data, we analyzed whether 
p21 overexpression affects IFN-g production. 
After initial TCR stimulation and IL-2 expansion, 
we stimulated the cells with IL-12 and IL-18, 
which are known to synergistically induce 
IFN-g production (Robinson et al., 1997). As 
a result, B6/lpr T cells showed a high capacity 
to produce IFN-g, whereas in B6/lpr-p21tg T 
cells,	 p21	 transgenic	 expression	 significantly	
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FIGURE 1 | p21 overexpression reduces activation of effector and memory CD4+ T cells in B6lpr-p21tg mice. 
Surface expression of CD69 activation marker in lymph node CD62LhiCD44hi effector (A) and CD62LloCD44hi memory 
(B) CD4+ T cells from 4-month-old B6/lpr, B6/lpr-p21tg,	B6	and	B6-p21tg	mice,	as	determined	by	flow	cytometry.	Data	
show representative experiment of two performed (n = 4 mice).
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reduced the proportion of IFN-g-producing 
cells (Figure 3). These data show that p21 
overexpression suppresses IL-12- and IL-18-
dependent IFN-g production in effector/memory 
CD4+ T cells, and suggest that p21 could control 
intrinsic T cell activation independently of TCR 
stimulation.
Reduced IFN-g production in B6/lpr-p21tg T 
cells has a paracrine effect on macrophage 
activation
T cell-directed p21 overexpression in B6/
lpr mice reduced the proportions of IFN-g-
secreting effector/memory T cells, thereby 
reducing autoantibody production and disease 
FIGURE 2 | p21 overexpression reduces IFN-g production in B6lpr-p21tg effector and memory T cells. Lymph 
node cells from 4-month-old B6/lpr, B6/lpr-p21tg, B6 and B6-p21tg mice were stimulated ex vivo with PMA (50 ng/ml) 
and ionomycin (2 m/ml) for 4h and analyzed for intracellular IFN-g. Flow cytometry analysis showing the frequency of 
IFN-g-producing CD62LhiCD44hi effector (A) and CD62LloCD44hi memory (B) CD4+ T cells. (C) The frequency of IFN-g-
producing small CD44hi CD4+ memory T cells in B6/lpr, B6/lpr-p21tg, B6 and B6-p21tg mice. Data show representative 
experiment of two performed (n = 4 mice).
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manifestations in these mice (Daszkiewicz et 
al., 2015). As macrophage activation is critical 
for lpr disease development (Carvalho-Pinto 
et al., 2002), we investigated whether p21 
overexpression in T cells has a paracrine 
effect on macrophage activation. Peritoneal 
B6/lpr macrophages were exposed to culture 
supernatants of repeatedly stimulated B6/
lpr and B6/lpr-p21tg T cells. The IFN-g 
concentration in T cell culture supernatants was 
strongly reduced in the presence of the p21 
transgene (Figure 4A). Whereas B6/lpr T cell 
supernatants strongly activated macrophages, 
seen as high STAT1 phosphorylation and 
iNOS protein levels, equivalent supernatants 
from B6/lpr-p21tg T cells induced very low 
p-STAT1 levels and iNOS was undetectable 
(Figure 4B). These data suggest that large 
amounts of IFN-g are needed to induce 
iNOS,	 which	 was	 confirmed	 by	 stimulating	
macrophages at different IFN-g concentrations 
(Figure 4B). The results highlight the potential 
of p21 overexpression to control disease in a 
paracrine fashion.
100 101 102 103
36.7 ± 1.6% 17.5 ± 1.8%
Re
la
tiv
e 
ce
ll 
co
un
t
IFN-γ
B6/lpr CD4+ T cells B6/lpr-p21tg CD4+ T cells
0
20
40
60
80
100
0
20
40
60
80
100
Re
la
tiv
e 
ce
ll 
co
un
t
100 101 102 103
IFN-γ
FIGURE 3 | p21 overexpression decreases IFN-g induction by IL-12 and IL-18 in B6lpr-p21tg effector/memory T 
cells after in vitro repeated stimulation. CD4+ T cells from B6/lpr and B6/lpr-p21tg mouse spleens were stimulated 
with ConA for 24 h, expanded in presence of IL-2 for 6 days, and restimulated with IL-12 and IL-18 in the presence of 
IL-2 for 24 h. Flow cytometry analysis showing the frequency of IFN-g-producing effector/memory CD4+ T cells. Data 
show mean ± SEM (n = 3); p = 0.0013, two-tailed Student’s t test.  
P-STAT1
iNOS
β-actin
B6
/lp
r s
up
.
B6
/lp
r-p
21
tg
 su
p.
IFN
-γ 
10
0U
/m
l
IFN
-γ 
50
U/
ml
co
nt
ro
l
0 4 24 (h)ConA
500
1000
5000
10000
15000
20000
25000 B6/lpr
B6/lpr-p21tg
IF
N
-γ
 (p
g/
m
l)
A
0
B
FIGURE 4 | Decreased B6/lpr macrophage activation by B6lpr-p21tg T cell culture supernatant. (A) IFN-g 
concentrations in supernatants from B6/lpr and B6/lpr-p21tg T cell cultures after secondary ConA stimulation. (B) 
Left, Immunoblot analysis showing STAT1 phosphorylation and iNOS protein levels in B6/lpr peritoneal macrophages 
exposed to supernatants from B6/lpr and B6/lpr-p21tg T cells repeatedly stimulated with ConA. Right, p-STAT1 
and iNOS levels in B6/lpr peritoneal macrophages after stimulation with different concentrations of IFN-g. Shown is 
representative experiment of 3 performed.
47RESULTS 47
Lack of p21 increases B6/lpr effector/
memory CD4+T cell generation and IFN-g 
production
Since our results indicated that p21 
expression is important in the control of 
apoptosis-resistant memory T cell proliferation 
and	activation,	we	generated	p21-deficient	B6/
lpr mice to determine whether the lack of p21 
has an effect on the hyperactivation status 
of B6/lpr T cells. Indeed, p21-/-B6/lpr mice 
showed even higher effector/memory CD4+ T 
cell activation and accumulation than B6/lpr 
mice; this aggravated autoimmune pathology 
in the p21-/-B6/lpr mice, which was only mild in 
the B6/lpr mice, and led to increased mortality 
(our unpublished observations). We therefore 
examined the activation status of these cells 
and their IFN-g-producing potential after in vitro 
repeated stimulation. After a second stimulation 
with IL-12 and IL-18, B6/lpr T cells showed 
increased proportions of CD44hiCD62Llo 
memory cells compared with B6 mice, which 
showed a predominant naïve CD44loCD62Lhi 
phenotype (Figure 5A). Strikingly, the p21-
deficient	 mice	 showed	 further	 increased	
proportions of CD44hiCD62Llo memory T cells 
in comparison with B6/lpr mice (Figure 5A). We 
next analyzed the activation of these cells and 
found	significantly	 increased	 IFN-g production 
in CD44hiCD62Llo p21-/-B6/lpr compared 
with B6/lpr memory T cells (Figure 5B). p21 
deficiency	 thus	 increases	 generation	 of	 Fas-
deficient	 effector/memory	 T	 cells	 as	 well	 as	
their IFN-g-producing potential.
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FIGURE 5 | Lack of p21 further enhances the accumulation of IFN-g-producing B6lpr memory T cells. CD4+ T 
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with Bonferroni correction. (B) The frequency of IFN-g-producing CD44hiCD62Llo memory CD4+ T cells. Data show 
mean ± SEM (n = 3); *p<0.05, two-tailed Student’s t test.
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Elevated IFN-g production by p21-/- effector/
memory CD4+ T cells
To study whether p21 controls IFN-g 
production in effector/memory CD4+ T cells 
independently of lack of Fas, we examined 
IL-12- and IL-18-dependent IFN-g induction 
in WT (B6) and p21-/- effector/memory T 
cells obtained after in vitro TCR-dependent 
stimulation and IL-2 expansion. While IL-12 
combined	 with	 IL-18	 induced	 significantly	
higher levels of IFN-g in p21-/- compared with 
WT effector/memory T cells (Figure 6A, left 
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panels), the levels of IFN-g induced by IL-12 
alone were similar in WT and p21-/- cells 
(Figure 6A, right panel). These data suggested 
that p21 negatively controls the signaling 
downstream of IL-18 and not of IL-12. Further 
analysis of the effector/memory T cell subsets 
revealed that lack of p21 led to increased 
generation of CD44hiCD62Llo memory cells, 
which	resulted	in	significantly	lower	proportions	
of naïve CD44loCD62Lhi cells in comparison 
with WT cells (Figure 6B). To exclude the 
possibility that increased IFN-g production 
is a result of the increased percentage of 
p21-/- CD44hiCD62Llo cells, we analyzed IFN-g 
production within the CD44hiCD62Llo gate. After 
IL-12/IL-18	stimulation,	lack	of	p21	significantly	
increased the proportions of IFN-g-producing 
CD44hiCD62Llo memory T cells compared 
with WT cells, with no such effect during IL-12 
stimulation	alone	(Figure	6C).	Deficiency	in	p21	
therefore increases the generation of effector/
memory T cells and their activation via IL-18.
Lack of p21 increases NF-kB DNA binding 
activity in effector/memory CD4+ T cells
To obtain mechanistic insight into how p21 
regulates IFN-g production, we analyzed the 
IL12/IL-18-dependent activation of STAT4 and 
NF-kB, respectively (Robinson et al., 1997; 
Nakahira et al., 2002). Electrophoretic mobility 
shift assay (EMSA) analysis showed markedly 
increased NF-kB activation in p21-/- compared 
with WT effector/memory T cells at 1 h post-
IL-12/IL-18 stimulation (Figure 7A). We also 
detected high levels of phosphorylated STAT4 
in p21-/- effector/memory T cells at 2 h post-
IL-12/IL-18 stimulation (Figure 7B). This was 
unexpected, since p21 expression had no effect 
on IFN-g production induced by IL-12 alone. 
High NF-kB activation and/or IFN-g production 
induced by IL-18 contributes to increased IL-12 
receptor expression and consequently, STAT4 
phosphorylation (Aita et al., 2004; Wu et al., 
2000). Lack of p21 therefore enhances IFN-g 
production in effector/memory CD4+ T cells 
through its effect on IL-18-dependent NF-kB 
activation.
p21 regulates the production of mROS in 
effector/memory CD4+ T cells
Signaling events dependent on mitochondrial 
reactive oxygen species (mROS) are needed 
for correct TCR-dependent activation and IL-2 
production (Sena et al., 2013). We therefore 
0 1 2 4 24 0 1 2 4 24 (h)
p-STAT4
p21
β-actin
WT p21-/-
1 2 1 2 (h)
WT p21-/-
NF-κB
A B
FIGURE 7 | Increased STAT4 and NF-kB activation in effector/memory T cells in absence of p21. CD4+ T cells 
from WT and p21-/- mouse spleens were stimulated with ConA for 24 h, expanded in presence of IL-2 for 6 days, and 
restimulated with IL-12 and IL-18 in the presence of IL-2 for 24 h. (A) EMSA analysis of nuclear extracts showing NF-kB 
protein complexes binding the consensus DNA sequence. (B) Immunoblot showing phospho-STAT4 and p21 protein 
levels in whole cell lysates. Equal loading is visualized by b-actin expression. Data show representative experiment of 
two performed.
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considered that p21 might regulate NF-kB 
activation and IFN-g production in effector/
memory T cells through an effect on mROS.
We	 first	 examined	 IL-12/IL-18-dependent	
mROS induction in WT and p21-/- effector/
memory T cells obtained after in vitro TCR-
dependent stimulation and IL-2 expansion. 
Using the MitoSOX Red dye, which detects 
mitochondrial superoxide production in live 
cells, we found that p21-/- effector/memory T cells 
showed elevated mROS production compared 
with WT cells, at early times after IL-12/IL-18 
stimulation (Figure 8A). To test whether p21 
expression affects mROS production after 
TCR-dependent stimulation, we performed a 
second stimulation with concavalin A (ConA). 
mROS production was again clearly elevated 
in p21-/- effector/memory compared with WT T 
cells, at 30 and 60 min post-ConA restimulation 
(Figure 8B). Finally, we performed antigen-
specific	 stimulation	 using	 transgenic	 T	 cells	
expressing	a	TCR	specific	for	chicken	ovalbumin	
(OVA), which were isolated from OT-II and 
p21-/-OT-II mice (Robertson et al., 2000). These 
T cells were stimulated in vitro in the presence 
of OVA-presenting dendritic cells, expanded 
for 6 days with IL-2, and restimulated with the 
same cells (Figure 9A). Early after second 
antigen-specific	 stimulation,	 p21	 deficiency	
led to elevated mROS production in effector/
memory T cells (Figure 9B). Collectively, these 
data show that lack of p21 leads to increased 
mROS production in effector/memory T cells, 
after both TCR-dependent and -independent 
stimulation.
FIGURE 8 | Mitochondrial superoxide production is increased in effector/memory T cells in absence of p21. 
Flow	cytometry	analysis	of	mROS	production	measured	by	mitoSOX	Red	fluorescence.	CD4+ T cells from WT and 
p21-/- mouse spleens were stimulated with ConA for 24 h, expanded in presence of IL-2 for 6 days, and restimulated 
with IL-12 and IL-18 (A) or ConA (B) for indicated time points. Histograms show representative staining. Median 
fluorescence	intensities	were	normalized	to	the	unstimulated	cells	of	each	genotype.	Graphs	show	mean	±	SEM	(n = 
3); *p<0.05, two-way ANOVA with Bonferroni correction.
0
20
40
60
80
100
Re
la
tiv
e 
ce
ll 
co
un
t
100 101 102 103
MitoSOX
100 101 102 103 100 101 102 103
WT p21-/-Unstimulated
15’ 30’ 60’
0
10
20
30
15’ 30’ 60’
M
ito
SO
X
(r
el
at
iv
e 
u
or
es
ce
nc
e)
0
40
*
WT
p21-/-
0
20
40
60
80
100
Re
la
tiv
e 
ce
ll 
co
un
t
100 101 102 103
MitoSOX
100 101 102 103 100 101 102 103
WT p21-/-Unstimulated
15’ 30’ 60’
*
0
0.5
1.0
1.5
2.0
2.5
15’ 30’ 60’0
M
ito
SO
X
(r
el
at
iv
e 
u
or
es
ce
nc
e)
WT
p21-/-
A
B
51RESULTS 51
Inhibition of mitochondrial ROS reduces 
IFN-g production in CD4+ effector/memory 
T cells
To determine whether mROS are functionally 
important for IL-12/IL-18-induced IFN-g 
production, we treated the cells with mROS 
inhibitor prior to the second stimulation. The 
major source of ROS is mitochondrial oxidative 
phosphorylation, as electron leakage occurs at 
complex I, complex II and complex III, converting 
oxygen to superoxide (Li and Trush 1998). 
DPI (diphenyleneiodonium) blocks mROS by 
inhibiting	 FAD	 (flavin	 adenine	 dinucleotide),	
which is present at both mitochondrial complex 
I (NADH-quinone oxidoreductase) and complex 
II (succinyl dehydrogenase) (Figure 10A). 
Using the MitoSOX Red dye, we found that 
DPI	 treatment	 significantly	 reduced	 mROS	
levels in both WT and p21-/- effector/memory T 
cells after second stimulation with IL-12/IL-18 
(Figure 10B). mROS levels were similar in WT 
and p21-/- cells after DPI treatment, indicating 
that lack of p21 might increase mROS through 
complex I or complex II (Figure 10B). IFN-g 
production was severely reduced by DPI 
treatment in both WT and p21-/- effector/memory 
T cells (Figure 10C). These data identify mROS 
as an important signaling component for IL-12/
IL-18-induced IFN-g production, both in normal 
and	 in	 p21-deficient	 hyperactivated	 effector/
memory CD4+ T cells, and point to p21 as a 
regulator of mitochondrial complexes I and II.
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FIGURE 9 | Increased mitochondrial superoxide production after antigen-specific stimulation of p21-deficient 
effector/memory T cells. (A) CD4+ T cells from OT-II and p21-/-OT-II mouse spleens were incubated with OVA-
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Mitochondrial ROS promote the 
accumulation of CD44hi effector/memory T 
cells
Mitochondrial metabolism has an important 
role in memory T cell differentiation (Pearce et 
al., 2009). We therefore evaluated whether p21 
regulates effector/memory T cell generation, 
through its effect on mROS production. To 
assess the capacity of WT and p21-/- CD4+ 
100
101
102
103
100
101
102
103
IFN-γ
IFN-γ
WT p21-/-
IL-12 & IL-18
IL-12 & IL-18 & DPI
IL-2
***
***
%
 IF
N
-γ
+  c
el
ls
0
20
10
30
WT p21-/-
WT p21-/-
0
0.5
1.0
1.5
M
ito
SO
X
(re
la
tiv
e 
u
or
es
ce
nc
e)
*
***
A
B
**
***
CoQ
e- e-
NADH NAD+
FAD FADH2
e-
H+
O2 + 4H
+ 2H2O
e-
ADP + Pi ATP
H+
H+
H+CytC
e-
H+
Outer
mitochondrial
membrane
Intermembrane 
space
Inner 
mitochondrial
membrane
Matrix
Complex III
Complex I
Complex II
Complex IV
Complex V
O2
-
O2
-
O2
- O2
-O2
-
DPI
C
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CD44hi memory phenotype (Figure 11). We 
observed no marked effect of DPI treatment 
on cell viability (Figure 12). These results 
identify mROS as a driver of memory T cell 
differentiation, and suggest that p21 controls 
memory T cell accumulation and activation by 
regulating mROS.
FIGURE 11 | Inhibition of mitochondrial ROS reduces CD44+ effector/memory T cell accumulation. CD4+ T cells 
from WT and p21-/- mouse spleens were stimulated with ConA for 24 h, expanded in presence of IL-2 for 6 days, and 
restimulated with IL-12 and IL-18 alone or in the presence of indicated antioxidants for 24 h. CD44 expression was 
determined	by	flow	cytometry.	Representative	dot	plots	are	shown.	Graphs	show	mean	±	SEM	(n = 3); ***p<0.001, two-
way ANOVA with Bonferroni correction.
T cells to acquire memory phenotype, we 
analyzed CD44 expression after second 
stimulation with IL-12/IL-18. As shown above 
(Figures 5 and 6), lack of p21 led to increased 
accumulation of CD44hi effector/memory 
T cells (~30 vs. ~60%), and increased the 
percentage of IFN-g-producing CD44hi memory 
cells (~20 vs. ~40%) compared with WT cells 
(Figure 11). In addition to reducing the capacity 
of these cells to produce IFN-g (Figure 10C and 
Figure 11), DPI treatment severely altered their 
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not affect cell viability. Cell cycle 
analysis of B6 and p21-/- effector/
memory CD4+ T cells at 24 h post-
secondary stimulation with IL-12 
and IL-18. Representative data 
are shown (n = 3).
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p21 deficiency increases TCR-dependent 
NF-kB stimulation through mitochondrial 
ROS
p21 regulates effector/memory T cell 
activation after repeated in vitro TCR 
stimulation (Daszkiewicz et al., 2015). Our 
results	 identified	p21	as	a	regulator	of	mROS	
production after repeated TCR stimulation 
(Figures 8 and 9). We therefore tested whether 
these increased mROS in p21-/- cells have 
an effect on NF-kB activation downstream 
of the TCR. After a second TCR stimulation, 
we detected elevated p65 phosphorylation 
in p21-/- compared with WT effector/memory 
T cells (Figure 13). After DPI treatment, p65 
phosphorylation was reduced in p21-/- effector/
memory T cells, and was reverted to the levels 
of WT cells (Figure 13). p21 protein levels were 
unaffected by DPI treatment (Figure 13), which 
showed that p21 acts upstream of mROS. 
These	 findings	 identify	 p21	 as	 an	 important	
regulator of mROS production during effector/
memory T cell activation. This role of p21 is 
independent of its CDK2 inhibitor function (our 
unpublished data).
p21 deficiency increases antigen-specific 
CD4+ T cell-dependent inflammation in vivo
To	determine	whether	p21	deficiency	would	
affect the progression of a CD4+ T cell-dependent 
inflammatory	disease,	we	used	the	OVA	model	
of	 allergic	 asthma.	 Lung	 inflammation	 in	 this	
model is entirely dependent on CD4+ T cells 
(Afshar et al., 2008). WT and p21-/- mice were 
sensitized with OVA plus alum at day 0 and 
day 10, and then aerosol challenged daily 
from day 19 to day 24 for 20 min with OVA, 
and	 sacrificed	 24	 h	 after	 the	 final	 treatment	
for	analysis	of	lung	inflammation	(Bryce	et	al.,	
2006). Control mice were sensitized with alum 
alone and aerosol challenged with PBS. In WT 
mice, histological analysis of the lung revealed 
mild	peribronchiolar	and	perivascular	infiltration	
of macrophages, lymphocytes, eosinophils and 
neutrophils.	In	contrast,	p21-deficient	mice	had	
severe pneumonitis with striking perivascular 
and	 interstitial	 inflammation,	which	suggested	
that p21 is necessary to control the level of 
chronic	 inflammation	 in	 lungs	 (Figure	 14A).	
In accordance with this, circulating levels of 
OVA-specific	 immunoglobulin	 E	 (IgE)	 were	
significantly	 increased	 in	p21-/- compared with 
WT mice (Figure 14B). IgE production is a B 
cell function that requires assistance from 
CD4+ T cells for activation and class switching. 
Elevated IgE production in p21-/- mice therefore 
concurs with their CD4+ T cell hyperactivation, 
although we cannot rule out the possibility of 
intrinsic hyperactivation of p21-/- B cells. In any 
case, this model provides evidence that p21 is 
an essential regulator of the immune response, 
not only in the context of autoimmunity, but also 
in	other	settings	such	as	lung	inflammation.
FIGURE 13 | Inhibition of mitochondrial ROS reverts 
high NF-kB activation in p21-deficient effector/
memory CD4+ T cells. CD4+ T cells from WT and 
p21-/- mouse spleens were stimulated with ConA for 
24 h, expanded in presence of IL-2 for 6 days, and 
restimulated with IL-12 and IL-18 alone or in the presence 
of DPI for indicated times. Immunoblot analysis shows 
phosphorilated p65 protein levels in whole cell extracts. 
p21 expression was not affected by DPI treatment. Equal 
loading is visualized by b-actin expression. Data show 
representative experiment of two performed. 
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FIGURE 14 | p21 deficiency aggravates CD4+ T cell-dependent airway inflammation in vivo. (A) Lung sections 
subjected	 to	 hematoxylin	 and	 eosin	 staining	 showing	 impressive	 peribronchiolar	 and	 perivascular	 inflammation	
in p21-/- mice compared with WT after OVA aerosol challenge. (B)	Serum	OVA-specific	 IgE	 levels	as	measured	by	
sandwich ELISA. Data show median (n = 5 mice); *p<0.05, Mann-Whitney test, U = 2. 
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57RESULTS 57
A previous study from our laboratory 
demonstrated that p21 negatively regulates 
IKK complex activity in LPS-activated macro-
phages (Trakala et al., 2009), and therefore, 
NFkB; the underlying mechanism nonetheless 
remained poorly understood. TLR4 activation 
leads to TRAF6-dependent activation of the 
TAK1 kinase, which in turn activates two dis-
tinct pathways involving the IKK complex and 
MAPK (ERK, JNK and p38) (Kawai and Akira, 
2007). A recent study showed that TRAF6 can 
translocate to the mitochondria, where it inter-
acts with proteins involved in the mitochondrial 
respiratory chain, leading to increased mito-
chondrial and cellular ROS generation (West 
et al., 2011a). Mounting evidence indicates 
that mROS, induced by TLR4 activation, facil-
itate	bacterial	phagocytosis	and	pro-inflamma-
tory cytokine production through redox-sensi-
tive activation of the IKK complex and NF-kB 
(Bai et al., 2005; Gloire et al., 2006; West et 
al., 2011b). We therefore analyzed whether 
p21	 deficiency	 affects	 mROS	 generation	 in	
LPS-activated macrophages, leading to elevat-
ed NF-kB activity.
p21 deficiency increases generation of 
mitochondrial and cellular reactive oxygen 
species in LPS-activated macrophages
Consistent with previous reports, LPS 
stimulation vigorously upregulated p21 
expression in WT peritoneal macrophages, at 
early times post-stimulation (Figure 15A, left). 
p21 levels reached a peak at 2 h post-LPS 
challenge	and	remained	high	at	4	h,	as	confirmed	
by RT-PCR analysis (Figure 15A, right). We next 
examined the levels of cellular ROS in LPS-
activated bone marrow-derived macrophages 
(BMDM), using the CM-H2DCFDA indicator, 
which detects total cellular H2O2 in live cells. 
Cellular ROS levels were notably increased 
as early as 15 min after LPS activation, and 
remained	 significantly	 higher	 in	 p21-deficient	
macrophages than in WT controls until 1 h 
post-LPS challenge (Figure 15B). Using the 
MitoSOX Red dye, which detects mitochondrial 
superoxide production in live cells, we found 
elevated mROS production, which peaked 
as early as 15 min post-LPS stimulation, and 
remained higher in p21-/- macrophages than in 
WT controls (Figure 15C). Overall, these data 
show that after LPS stimulation, lack of p21 
leads to increased mitochondrial superoxide 
production and accumulation of cellular H2O2, 
which could account for the increased IKK 
complex activity, leading to more vigorous IkBa 
degradation and higher NF-kB binding activity 
in p21-/- compared with WT macrophages.
p21 deficiency affects IkBa degradation, 
but not MAPK or IRF3 activation in LPS-
stimulated macrophages
To understand how lack of p21 mediates 
increased NF-kB activation, and whether 
increased mitochondrial ROS activate other 
signaling molecules in the absence of p21, we 
examined the activation of MyD88-dependent 
and independent pathways, which are activated 
by TLR4 stimulation. There was no detectable 
difference in interferon regulatory factor 3 (IRF3) 
Chapter 2: p21 regulates LPS-induced mitochondrial reactive 
oxygen species and DNA binding of p65/p50 NF-kB
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phosphorylation in LPS-activated WT and p21-/- 
macrophages (Figure 16A), indicating that lack 
of p21 does not affect the MyD88-independent 
pathway. We next analyzed phosphorylation 
of JNK and ERK, both downstream activation 
indicators of the MyD88-dependent pathway, 
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FIGURE 15 | Cellular and mitochondrial ROS are augmented in LPS-activated macrophages in absence of p21. 
(A) WT and p21-/- BMDMs were stimulated with 100 ng/ml LPS for indicated times and analyzed by Western blot (left) 
and RT-PCR (right) for p21 expression. b-actin is used as a housekeeping control. Data show mean ± SEM (n = 3); 
***p<0.001, two-tailed Student’s t test. Flow cytometry analysis of cellular H2O2 levels measured by CM-H2DCFDA (B) 
and	mROS	production	measured	by	mitoSOX	Red	fluorescence	(C) at indicated times post-LPS stimulation. Histograms 
show	representative	staining.	Median	fluorescence	intensities	were	normalized	to	unstimulated	WT	cells.	Graphs	show	
mean ± SEM (n = 3); *p<0.05; **p<0.01; ***p<0.001, two-way ANOVA with Bonferroni correction.
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and found no differences between WT and 
p21-/- LPS-activated macrophages (Figure 16B 
and C). In agreement with a previous study 
(Trakala et al., 2009), IkBa degradation 
was more vigorous in p21-/- than in WT 
macrophages, which is indicative of increased 
NF-kB activation (Figure 16D). These data 
show that p21 suppresses exclusively NF-kB 
activation through negative regulation of IKK 
complex activity, without affecting the MAPK 
and MyD88-independent pathways.
p21 deficiency leads to enhanced LPS-
induced IFN-g production in macrophages
We	next	determined	whether	p21	deficiency	
affects the production of TNF-a and IFN-b, 
end products of the MyD88-dependent and 
-independent pathways, respectively (Akira 
and Takeda, 2004). Consistent with previous 
reports, TNF-a levels were elevated in 
culture supernatants of LPS-stimulated p21-/- 
compared with WT macrophages (Figure 17A). 
We also found increased IFN-b levels in 
culture supernatants of p21-/- compared with 
WT macrophages (Figure 17A), in spite of 
similar IRF3 phosphorylation in p21-/- and 
WT macrophages. This suggested that the 
increased IFN-b production is a consequence 
of increased NF-kB activation in the absence 
of p21.
LPS-induced IFN-b activates IFNAR 
(IFN-a/b receptor) in an autocrine manner, 
leading to STAT1 phosphorylation and 
transcription of IFN-inducible genes such 
as iNOS and CXCL11 (Akira and Takeda, 
2004). We thus tested whether elevated IFN-b 
production in the absence of p21 translates 
into increased activation of IFNAR downstream 
events. Consistent with previous reports, 
STAT1 phosphorylation is a late event and 
was detectable at 1 h post-LPS stimulation 
(Figure 17B). Although it appears that p-STAT1 
is increased in p21-/- compared with WT 
macrophages at 1 h post-LPS stimulation, 
p-STAT1 reached saturating levels at the 2 h 
time point and remained high at 4 h in both 
WT and p21-/- macrophages (Figure 17B). 
Coinciding	with	this	finding,	iNOS	and	CXCL11	
were strongly induced, with no differences 
between WT and p21-/- macrophages 
(Figure 17C). Although p21-/- LPS-activated 
macrophages produce increased amounts of 
IFN-b, autocrine IFN-b stimulation in WT cells 
is	sufficient	 to	achieve	maximum	activation	of	
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FIGURE 16 | Lack of p21 affects IkBa degradation, 
but not IRF3 and MAPK pathways in LPS-activated 
macrophages. Immunoblot analysis shows the 
phosphorylation of IRF3 (A), JNK (B), ERK (C) and 
IkBa degradation (D) in whole cell lysates of peritoneal 
macrophages from WT and p21-/- mice stimulated with 
100 ng/ml LPS for indicated times. Equal loading is 
visualized by b-actin expression. Representative results 
of 2 independent experiments are shown.
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IFN-dependent events, at least up to 4 h post-
stimulation.
p21 deficiency increases NF-kB DNA 
binding and promotes the binding of 
active p65/p50 complex in LPS-activated 
macrophages
Our data, together with previous studies, 
suggested that p21 negatively regulates 
proinflammatory	cytokine	and	IFN-b production 
through NF-kB. We thus examined the DNA-
binding activity of NF-kB in nuclear extracts 
of WT and p21-/- LPS-activated macrophages, 
using EMSA. Using a [32P]-labeled consensus 
probe, we detected notably higher NF-kB DNA 
binding	 activity	 in	 p21-deficient	 compared	
with WT macrophages, at all times post-LPS 
stimulation (Figure 18A, compare lanes 2 and 
5). To determine how NF-kB binding affects 
IFN-b gene expression, we used the NF-kB 
element from the IFN-b promoter (Garoufalis 
et al., 1994), which differs from the consensus 
NF-kB sequence and serves as a more 
accurate estimation of the effect of NF-kB 
activation on IFN-b regulation. Using a [32P]-
labeled IFN-b-specific	 NF-kB probe, we also 
detected much higher NF-kB DNA binding 
activity	 in	 p21-deficient	 compared	 with	 WT	
macrophages, at all times post-LPS stimulation 
(Figure 18B, compare lanes 2 and 5). Control 
experiments using excess unlabeled or mutant 
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FIGURE 17 | p21 deficiency increases LPS-induced TNF-a and IFN-b production in macrophages. Peritoneal 
macrophages from WT and p21-/- mice were stimulated with 100 ng/ml LPS for indicated times. (A) Cytokine concentrations 
in culture supernatants at different time points after LPS stimulation, as measured by ELISA. Data show mean ± 
SEM (n = 3); **p<0.01, two-way ANOVA with Bonferroni correction. (B) Immunoblot showing the phosphorylation of 
STAT1 in whole cell lysates. Equal loading is visualized by b-actin expression. Representative results of 3 independent 
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NF-kB	oligonucleotides	indicated	the	specificity	
of the complexes detected (Figure 18A and B, 
lane 1).
To examine NF-kB complex composition 
in WT and p21-/- LPS-activated macrophages, 
we performed supershift analysis using 
antibodies	 specific	 for	 p65	 and	 p50	 NF-kB 
subunits. Anti-p50 antibody supershifted the 
entire NF-kB/DNA complex (Figure 18A and 
B, lanes 3 and 6), consistent with the fact 
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FIGURE 18 | p21 acts as a negative regulator of NF-kB activity. Nuclear extracts of WT and p21-/- peritoneal mac-
rophages treated with LPS (100 ng/ml) for indicated times, were incubated with [32P]-labeled NF-kB consensus (A) of 
IFN-b-specific	(B) probe and NF-kB DNA binding activity was analysed by EMSA. Anti-p65 and -p50 antibodies were 
used for supershift analysis. (C) Equal binding to NF-Y probe was used to verify the quality of nuclear extracts. In all 
gels,	first	lane	is	negative	control	showing	unspecific	binding.	Representative	results	of	2	independent	experiments	are	
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that two most abundant forms of NF-kB in 
TLR (Toll-like receptor) signaling are active 
p65/p50 heterodimers and inhibitory p50/
p50 homodimers (Kawai and Akira, 2007). 
By contrast, anti-p65 antibody supershifted 
only the p65/p50 portion of the DNA/protein 
complex, while the p50/p50 portion remained 
unaffected (Figure 18A and B, lanes 4 and 7). 
This	observation	allowed	 the	quantification	of	
the relative amounts of p65/p50 vs. p50/p50 
complexes. At early times post-LPS stimulation, 
the predominant NF-kB form bound to DNA was 
active p65/p50 NF-kB, at both the consensus 
and the IFN-b-specific	sequences	(Figure	18A	
and B, lanes 4 and 7). At later times, a shift in 
the subunit proportion was observed, indicating 
the predominance of inhibitory p50/p50 NF-kB 
complexes unaffected by supershift, at both the 
consensus and the IFN-b-specific	 sequences	
(Figure 18A and B, lanes 4 and 7). The NF-kB 
subunit composition pattern was similar in WT 
and p21-/- LPS-activated macrophages for 
both sequences tested, although at 1 h post-
stimulation, the absence of p21 favored a larger 
proportion	of	active	p65/p50	complex,	reflecting	
greater activation potential (Figure 19A and 
B). During LPS activation, lack of p21 thus 
increased overall NF-kB activity, as previously 
shown (Trakala et al., 2009), but also exerted 
a previously unreported effect in potentiating 
the predominance of active p65/p50 over the 
inhibitory p50/50 NF-kB.
FIGURE 19 | p21 deficiency promotes DNA binding of active p65/p50 NF-kB subunits. Supershift analysis of 
WT and p21-/- macrophage nuclear extracts was performed using anti-p65 antibody as in Figure 18. The intensity of 
supershift was assessed by densitometry and plotted as the percent of supershifted complex at indicated time points of 
LPS stimulation. Graphs show the pattern of p65/p50 binding to consensus (A) and IFN-b-specific	(B) NF-kB sequence 
in WT and p21-/- macrophages. Data show mean (n = 3 measurements), ***p<0.001, two-way ANOVA. Representative 
results of 2 independent experiments are shown. 
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monitored for 72 h (Figure 20A). We observed 
a	significant	difference	in	survival	between	WT	
and p21-/- mice, since the majority of WT mice 
reached a tolerant state after the secondary 
LPS challenge, whereas p21-/- mice did not 
(~60% died by 24 h post-LPS challenge and 
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FIGURE 20 | p21 controls in vivo endotoxin tolerance. 
(A) WT and p21-/- mice received a sublethal LPS dose, 
followed by a lethal dose after 16 h. (B) p21-/- mice did not 
develop tolerance compared to WT mice, as represented 
by a Kaplan-Meier survival curve. n = 10 mice; **p<0.01, 
logrank (Mantel-Cox) test. (C) Serum levels of M1-
associated cytokines (TNF-a and IFN-b) in WT and p21-/- 
mice at 2 h post-second LPS injection, as measured by 
ELISA. Data show mean ± SD (n = 3 mice); *p<0.05, 
two-tailed Student’s t test.
p21	deficiency	in	mice	increases	sensitivity	
to LPS-induced septic shock and death (Trakala 
et al., 2009). Sepsis is a complex pathology 
characterized	 by	 proinflammatory	 reactions	
that are responsible for tissue damage and 
organ dysfunction in severe sepsis, concurrent 
with	 anti-inflammatory	 responses,	 which	
are implicated in leukocyte deactivation, 
development of endotoxin tolerance and 
enhanced susceptibility to secondary infections 
(Angus and van der Poll, 2013; Biswas and 
Lopez-Collazo, 2009). Endotoxin tolerance in 
macrophages leads to reprogramming from 
proinflammatory	M1	to	hyporesponsive	M2-like	
cells (Porta et al., 2009; Pena et al., 2011). We 
therefore hypothesized that p21 is involved not 
only	in	limiting	the	proinflammatory	responses,	
but	 also	 in	 promoting	 the	 anti-inflammatory	
response and development of endotoxin 
tolerance in macrophages.
In vivo role of p21 in endotoxin tolerance
A common approach to the study of 
endotoxin tolerance in mice is a model that 
mimics two consecutive pathogen infections 
(López-Collazo and Del Fresno, 2013). After 
priming with a sublethal LPS dose, mice develop 
tolerance and are able to survive subsequent 
lethal LPS challenge (Berg et al., 1995; 
Wysocka et al., 2001). We therefore inquired 
whether	 a	 high	 proinflammatory	 response	 in	
the absence of p21 would compromise LPS 
tolerance induction. To induce LPS tolerance 
in WT and p21-/- mice in vivo, we administered 
a sublethal LPS dose (30 mg), followed 16 h 
later by a lethal LPS dose (150 mg); mice were 
Chapter 3: p21 regulates M1 to M2 macrophage reprogramming 
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100% by 60 h, Figure 20B). For further analysis, 
we	assessed	proinflammatory	cytokine	profiles	
at 2 h after the second LPS delivery, and found 
increased serum levels of TNF-a and IFN-b in 
p21-/- compared with WT mice (Figure 20C). 
These data indicated that the compromised 
tolerance	is	linked	to	an	excess	of	inflammatory	
cytokines in p21-/- mice. Based on these results, 
we hypothesized that p21 is essential for the 
regulation of macrophage reprogramming from 
the	proinflammatory	M1	to	the	hyporesponsive	
M2 state.
p21 controls proinflammatory macrophage 
activity during in vivo LPS tolerance
The peritoneal cavity of unstimulated 
mice is characterized by the presence of 
CD11b+F4/80hi macrophages, also referred 
to as large peritoneal macrophages; i.p. LPS 
injection	 provokes	 an	 influx	 of	 functionally	
distinct CD11b+F4/80lo cells, called small 
peritoneal macrophages (Ghosn et al., 2010; 
Ní Gabhann et al., 2014; Singh et al., 2015). 
We tested whether lack of p21 affects these 
macrophage populations during in vivo 
induction of LPS tolerance.
The relative proportions of peritoneal 
CD11b+F4/80lo and CD11b+F4/80hi were similar 
in WT and p21-/- mice after dual PBS treatment, 
showing a preponderance of F4/80hi with a 
F4/80lo:F4/80hi ratio of ~10:90 (Figure 21A). 
After dual LPS treatment, this ratio changed to 
~50:50 in both WT and p21-/- mice (Figure 21B), 
reflecting	 no	 apparent	 differences	 in	 the	
macrophage populations in WT and p21-/- mice 
during LPS tolerance. Analysis of the activation 
state of these populations nonetheless showed 
a >2-fold increase in TNF-a production in 
p21-/- compared with WT F4/80lo macrophages, 
indicating a greatly elevated M1-like 
macrophage response in the absence of 
p21 (Figure 22A). In agreement with this, we 
detected markedly augmented expression of 
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FIGURE 21 | p21 limits M1 activity during in vivo endotoxin tolerance.  p21-/- and WT mice received two LPS doses 
as in Figure 20. Flow cytometry analysis of peritoneal macrophage populations at 2 h after dual PBS (A) and LPS (B) 
treatment. Representative plots show gated CD11bhiF4/80lo and CD11bhiF4/80hi macrophage populations. The relative 
percentages of these two populations within the total F4/80+ gate are shown below the plots and were similar for WT 
and p21-/- mice after dual LPS or PBS treatment. Data show mean ± SD (n	=	8	mice);	n.s.-not	significant.		
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activation	 and	 M1	 proinflammatory	 state.	
During in vivo LPS tolerization, the increased 
proinflammatory	state	of	macrophages	in	p21-/- 
mice thus appears to impair the development 
of tolerance and leads to death.
MHC (major histocompatibility complex) class II 
and CD40 activation markers in p21-/- compared 
with WT F4/80lo macrophages (Figure 22B). 
Although F4/80hi macrophages produced 
low TNF-a levels, lack of p21 increased the 
production of this cytokine (Figure 22C). MHC 
class II and CD40 markers were expressed 
strongly in WT F4/80hi macrophages (>80%) 
and did not increase further in the absence of 
p21 (Figure 22D). Collectively, these data show 
that although lack of p21 does not alter the 
relative proportions of peritoneal macrophage 
populations, it has a profound effect on their 
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FIGURE 22 | p21 limits proinflammatory activity during in vivo endotoxin tolerance. p21-/- and WT mice received 
two LPS doses as in Figure 20. (A) Intracellular staining showing TNF-a production and by the F4/80lo macrophage 
population at 2 h post-treatment. (B) Expression of activation markers MHCII and CD40 on cell surface of F4/80lo 
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p21 deficiency disrupts M1 to M2 
macrophage polarization during LPS 
tolerance in vitro
Our in vivo results suggested that lack of p21 
might promote M1 macrophage responses and 
interfere with M2 polarization during endotoxin 
tolerance. To examine this possibility, we studied 
the role of p21 in macrophage polarization 
during in vitro LPS tolerance. In macrophages, 
tolerance is induced by prolonged LPS 
treatment, which leads to acquisition of an M2 
phenotype and reduced responsiveness of M1-
associated genes after a second LPS challenge 
(Porta et al., 2009). To induce tolerance in vitro, 
murine peritoneal macrophages were treated 
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FIGURE 23| p21-/- macrophages show impaired ability to polarize to M2 cells during in vitro endotoxin tolerance. 
(A) Scheme showing the in vitro endotoxin tolerance model. Peritoneal macrophages from WT and p21-/- mice were 
tolerized with 100 ng/ml LPS for 20 h (Tol), washed with PBS, cultured in medium (2 h) and restimulated with 100 ng/ml 
LPS for 4 h (Tol + LPS). LPS-activated cells were stimulated with LPS for 4 h without previous tolerization (LPS). Cells 
left untreated were controls (Ctrl). Total RNA was extracted at 4 h after LPS treatment and analyzed for gene expression. 
Culture supernatants were also collected and analyzed for cytokine production. (B) RT-PCR analysis showed impaired 
upregulation of M2-associated genes in p21-/- compared with WT macrophages after tolerization. (C) RT-PCR showed 
upregulation of representative M1 cytokine genes in p21-/- compared with WT tolerized macrophages. Results were 
normalized to b-actin and represent fold induction over unstimulated WT cells.  In all cases data show mean ± SEM 
(n = 3 independent experiments), *p<0.05; **p<0.01; ***p<0.001, two-way ANOVA with Bonferroni correction.
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associated cytokine expression after LPS 
rechallenge (Figure 23C). IFN-b mRNA was 
upregulated in tolerized p21-/- macrophages 
even without LPS restimulation (Figure 23C), 
suggesting close linkage of p21 and IFN-b 
in the regulation of M1 to M2 macrophage 
reprogramming. 
In culture supernatants of LPS-restimulated 
macrophages, levels of M1 cytokines TNF-a 
and IFN-b	 were	 significantly	 elevated	 in	 the	
absence of p21 (Figure 24A), which further 
confirmed	 the	 role	 of	 p21	 in	 the	 control	 of	
macrophage tolerization. We also evaluated 
expression of IL-10, an M2-related cytokine 
that is upregulated during endotoxin tolerance 
(Porta et al., 2009), and found impaired IL-10 
induction in p21-/- macrophages (Figure 24B). 
In accordance with the role of p21 in M2 
with LPS (20 h), washed, allowed to rest 
(2 h) and restimulated with LPS (4 h) (Porta 
et al., 2009) (Figure 23A). This treatment was 
followed by RT-PCR analysis of prototypical 
M1 and M2 gene expression in unstimulated 
(Ctrl), activated (LPS), tolerized (Tol) and 
restimulated (Tol + LPS) macrophages. 
Whereas tolerant WT macrophages acquired 
an	M2	polarization	profile	characterized	by	high	
expression of prototypic M2 genes (arginase I, 
YM1, CCL17), expression of these genes was 
defective in p21-/- macrophages (Figure 23B). 
These results revealed a central role for p21 
in M1 to M2 macrophage reprogramming. In 
support of this view, WT macrophages were 
tolerized	 as	 reflected	 by	 downregulation	 of	
M1 genes (IL-1b, TNF-a, IFN-b), whereas 
p21-/- macrophages did not develop tolerance 
and	showed	significantly	higher	 levels	of	M1-
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polarization, we detected high p21 protein 
levels at early time points and up to 4 h post-
LPS restimulation (Figure 24C); p21 mRNA was 
significantly	induced	after	LPS	rechallenge	and	
reached levels similar to those observed in LPS-
activated cells (Figure 24D). It thus appears 
that p21 promotes M1 to M2 polarization 
during in vitro endotoxin tolerization, and that 
IFN-b regulation is essential in the control of 
this process.
Increased IFN-b production disrupts LPS 
tolerization in p21-deficient macrophages
Our data showed that lack of p21 leads to 
increased IFN-b production after LPS activation 
(Figure 17A), although these high IFN-b levels 
had no effect on downstream gene expression 
after 4 h of LPS stimulation (Figure 17B and C). 
Sustained IFN-b production might nonetheless 
disrupt the tolerization process after prolonged 
LPS exposure, by maintaining strong expression 
of IFN-b-dependent M1-associated genes 
such as iNOS and CXCL11 (Akira and Takeda, 
2004).	To	provide	a	 cause/effect	 confirmation	
for the role of p21 on IFN-b regulation during 
LPS tolerance, we examined whether lack of 
p21 promotes IFN-dependent events, such 
as STAT1 phosphorylation (p-STAT1) and 
M1-associated gene expression. Following 
LPS tolerization (time 0; Figure 25A), WT 
cells showed low p-STAT1 levels, indicative of 
effective tolerization, while p21-/- macrophages 
showed high p-STAT1 levels and resisted 
tolerization. After secondary LPS treatment, 
STAT1 phosphorylation remained considerably 
higher	in	p21-deficient	than	in	WT	macrophages	
at 15, 30, and 60 min (Figure 25A). The 
association of p21 with p-STAT1 regulation 
during tolerization was further supported, 
since	 lack	 of	 p21	 led	 to	 significantly	 higher	
iNOS and CXCL11 levels after LPS tolerization 
and restimulation (Figure 25B). These results 
support the hypothesis that p21 is critical for 
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induction of macrophage hyporesponsiveness, 
by regulating IFN-b-dependent STAT1 
activation. This view was reinforced by the 
elevated IFN-b production by p21-/- compared 
to WT macrophages (Figure 24A).
IFN-g neutralization promotes macrophage 
hyporesponsiveness and improves LPS 
tolerance in p21-/- mice
To provide direct evidence that lack of p21 
enhances IFN-b production and promotes 
STAT1 phosphorylation, we treated WT and 
p21-/- macrophage cultures with an IFN-b-
blocking antibody (or an isotype-matched 
control). Antibody treatment lasted for the 
20 h of LPS tolerization, after which cells 
were washed and LPS rechallenged. This 
antibody	 treatment	 efficiently	 reduced	 STAT1	
phosphorylation in p21-/- cells, resulting in 
similar p-STAT1 levels in WT and p21-/- cells 
after tolerization (time 0; Figure 26A) and 
after secondary LPS treatment (Figure 26A). 
Anti-IFN-b antibody treatment effectively 
reduced iNOS and CXCL11 expression in p21-/- 
restimulated macrophages, which reverted 
to the levels produced by WT cells, and also 
suppressed the expression of these genes in 
WT cells (Figure 26B). We detected no effect 
on endogenous IFN-b expression (Figure 26B). 
These results showed that IFN-b neutralization 
reduces M1 activity mediators in p21-/- 
macrophages during tolerization, and coincide 
with the view that elevated IFN-b production 
hinders the macrophage potential to attain a 
hyporesponsive state.
To determine whether the effects of elevated 
IFN-b production by p21-/- macrophages 
extended beyond the 20 h tolerization time 
frame, we initiated IFN-b neutralization 
treatment	 after	 tolerization.	 p21-deficient	
macrophages were tolerized with LPS 
(20 h), subsequently treated with an anti-IFN-b 
antibody, and LPS rechallenged. Antibody 
treatment reduced STAT1 phosphorylation 
and iNOS protein levels (Figure 26C). This 
indicates that IFN-b neutralization reverses 
the	 M1	 proinflammatory	 phenotype	 of	 p21-/- 
macrophages to a tolerant state, even when 
antibody is delivered after LPS tolerization, 
during LPS rechallenge. These data suggest 
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FIGURE 27 | Lack of p21 does not affect IRF3, MAPK 
and NF-kB pathways in LPS-tolerized macrophages. 
(A) Immunoblots showing IRF3, ERK and JNK 
phosphorylation, and IkBa degradation at indicated times 
after LPS stimulation of resting or tolerized macrophages. 
b-actin is included as a loading control. Shown is 
representative experiment of two performed. (B) IRAK-M 
was induced at similar levels in LPS-tolerized WT and 
p21-/- macrophages. Results were normalized to b-actin 
and represent fold induction over unstimulated WT cells. 
Data shown as mean ± SEM (n = 3).
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Lack of p21 does not affect IRF3, MAPK 
and NF-kB pathways in LPS-tolerized 
macrophages
To understand how lack of p21 mediates 
increased IFN-b production after repeated 
LPS stimulation in macrophages, we examined 
activation pathways associated with this 
cytokine. IFN-b expression can be activated 
in a MyD88-independent or -dependent 
manner, through IRF3 or NF-kB, respectively 
(Akira and Takeda, 2004). Analysis of the 
MyD88-independent pathway showed no 
detectable change in IRF3 phosphorylation in 
LPS-tolerized and -restimulated WT or p21-/- 
macrophages (Figure 27A), suggesting that 
lack of p21 does not affect this pathway. We next 
analyzed downstream activation indicators of 
the MyD88-dependent pathway such ERK and 
JNK phosphorylation and found no differences 
after secondary LPS challenge in WT and p21-/- 
cells	(Figure	27A).	As	p21	deficiency	 leads	to	
increased IkBa degradation (Figure 16D) and 
increased NF-kB activity after primary LPS 
treatment (Figure 18), we examined the degree 
of IkBa degradation after LPS treatment in 
that elevated IFN-b is a determinant factor in 
compromising p21-/- macrophage progression 
to hyporesponsiveness, and acts at all levels of 
the tolerization process.
To	confirm	 that	 IFN-b impairs macrophage 
hyporesponsiveness in vivo, p21-/- mice, which 
fail to develop tolerance after two consecutive 
LPS challenges, were treated with anti-IFNAR 
(interferon-a/b receptor) antibody 2 h before 
secondary LPS delivery. In accordance with 
our	findings	showing	 that	 IFN-b neutralization 
promotes the in vitro tolerization of p21-/- 
macrophages, in vivo anti-IFNAR treatment 
induced	 tolerance	 and	 significantly	 improved	
survival of p21-/- mice after dual LPS injection 
(Figure 26D). Our data support the idea that 
the inability of p21-/- macrophages to achieve 
the hyporesponsive state is directly associated 
to the potential of these cells to produce high 
IFN-b levels, and point to IFN-b as a major 
factor in disabling macrophage tolerization.
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FIGURE 28 | Impaired LPS tolerance in p21-/- 
macrophages is cell-cycle-independent. (A) 
In WT and p21-/- LPS-tolerized macrophage 
extracts, CDK2 was immunoprecipitated and its 
kinase activity was measured using histone H1 
as a substrate. Assay products were resolved in 
SDS-PAGE, and phosphorylated H1 was detected 
by autoradiography. (B) Immunoblot showing 
CDK2 protein levels in LPS-tolerized peritoneal 
macrophages. Equal loading is visualized by 
b-actin expression. Representative results of 2 
independent experiments are shown.
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tolerized macrophages. IkBa levels were 
similar in WT and p21-/- macrophages following 
LPS rechallenge, which indicated that lack 
of p21 does not affect the NF-kB pathway in 
LPS-tolerized macrophages (Figure 27A). As 
IRAK-M is an important negative regulator of 
the TLR4 pathway that is implicated in LPS 
tolerance (Kobayashi et al., 2002), we examined 
whether	p21	deficiency	affected	this	regulator.	
We found no differences in IRAK-M expression 
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p21 attenuates IFN-b expression by 
regulating the balance of p50/p50 and p65/
p50 NF-kB 
The fact that lack of p21 leads to enhanced 
NF-kB activity after LPS activation (Figure 18) 
led us to hypothesize that it would have a sim-
ilar effect in LPS-tolerized cells. To test this 
possibility, we examined DNA-binding activity 
of NF-kB in nuclear extracts of WT and p21-/- 
LPS-rechallenged macrophages by EMSA us-
ing a [32P]-labeled consensus NF-kB probe. 
We found that NF-kB activation was similar in 
WT and p21-/- LPS-tolerized macrophages at 
all time points following secondary stimulation 
(Figure 29A, compare lanes 2 and 5). As our 
data showed that IFN-b levels are determinant 
for	 the	 increased	 proinflammatory	 response	
of p21-/- macrophages after LPS tolerization 
and rechallenge (Figure 26), we analyzed how 
NF-kB activation affects IFN-b gene expres-
sion, using the NF-kB element from the IFN-b 
promoter (Garoufalis et al., 1994). Overall 
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FIGURE 30 | p21 deficiency modulates the balance between p65/p50 and p50/p50 NF-kB dimers in LPS toler-
ized macrophages. Supershift analysis of WT and p21-/- macrophage nuclear extracts was performed using anti-p65 
antibody as in Figure 29. The intensity of supershift was assessed by densitometry and plotted as the percent of super-
shifted complex at indicated time points of LPS stimulation. Graphs show the pattern of p65/p50 vs. p50/p50 binding to 
consensus (A) and IFN-b-specific	(B) NF-kB sequence in WT and p21-/- macrophages. Data show mean (n = 3 mea-
surements), ***p<0.001, two-way ANOVA. Representative results of 2 independent experiments are shown.  
between WT and p21-/- macrophages after LPS 
tolerization and rechallenge (Figure 27B).
Since LPS treatment in macrophages 
induces cell cycle arrest (Xaus et al., 1999) and 
p21 is cell cycle inhibitor, we evaluated whether 
p21	 deficiency	 affects	 the	 cell	 cycle	 after	
LPS tolerization. We examined activity and 
expression of CDK2, a p21 target, and found that 
CDK2 activity in LPS-tolerized macrophages 
was independent of p21 expression 
(Figure 28A). Moreover, CDK2 protein levels 
were similar in WT and p21-/- macrophages at 
all times post-LPS restimulation (Figure 28B). 
p21	deficiency	thus	did	not	affect	cell	cycling	in	
LPS-tolerized macrophages.
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NF-kB binding to the IFN-b-specific	sequence	
did not increase in p21-/- macrophages after 
LPS rechallenge (Figure 29B, compare lanes 
2 and 5), suggesting that p21 acts through two 
different mechanisms in LPS-activated and tol-
erized macrophages.
Following LPS tolerization, inhibitory p50 
NF-kB accumulates and forms homodimers 
that repress transcription of NF-kB target genes 
(Ziegler-Heitbrock, 2001). We hypothesized 
that lack of p21 could affect the balance of 
active p65/p50 and inhibitory p50/50 NF-kB 
complexes in favor of p65/50, and thus disrupt 
macrophage polarization and development 
of tolerance. To examine the NF-kB complex 
composition in WT and p21-/- LPS-rechallenged 
macrophages, we performed supershift 
analysis	 using	 antibodies	 specific	 for	 p65	
and p50 NF-kB subunits. Anti-p50 antibody 
supershifted the entire complex (Figure 29A 
and B, lanes 3 and 6), consistent with the fact 
that p65/p50 and p50/p50 forms of NF-kB 
are most abundant in this system (Kawai and 
Akira, 2007). By contrast, anti-p65 antibody 
supershifted only the p65/p50 portion of the 
DNA-protein complex, leaving the p50/p50 
portion	unaffected;	this	permitted	quantification	
of the relative amounts of p65/p50 vs. p50/
p50 complexes (Figure 29A and B, lanes 4 
and 7). At all times post-LPS rechallenge, the 
predominant NF-kB form bound to consensus 
sequence in WT macrophages was inhibitory 
p50/p50 (Figure 29A, lane 4 and Figure 30A), 
which corroborated the compromised 
inflammatory	status	of	tolerized	macrophages.	
In the case of p21-/-	macrophages,	 the	profile	
of NF-kB complex composition differed, and 
showed higher levels of p65/p50 over p50/p50 
complexes at 15 min post-secondary stimulation 
(Figure 29A, lane 7 and Figure 30A). At later 
times, however, the relative proportion of these 
complexes reverted to that of WT macrophages 
(Figure 29A, lane 7 and Figure 30A). These 
findings	 suggested	 that	 the	 inability	 of	 p21-/- 
macrophages to achieve a tolerant phenotype 
after secondary LPS stimulation is linked to 
altered balance of NF-kB complexes and 
delayed formation of inhibitory p50/p50 NF-kB 
in these cells.
Analysis of our data using an IFN-b-specific	
NF-kB probe showed a striking difference in 
NF-kB complex composition, with decreased 
proportions of p50/p50 homodimers in p21-/- 
compared to WT macrophages at 15 and 30 
min post-LPS rechallenge (Figure 29B, lanes 
4 and 7 and Figure 30B). We observed the 
most evident difference at 30 min post-LPS 
rechallenge, with a clear predominance of p50/
p50 homodimers in WT macrophages, while 
p65/p50 heterodimers were found in much 
larger proportions in p21-/- cells (Figure 29B, 
lanes 4 and 7 and Figure 30B). The NF-kB 
subunit-binding pattern was much more 
affected by the lack of p21 in the case of the 
IFN-b	promoter-specific	sequence	 than	 in	 the	
case of the consensus probe (Figure 30 A and 
B). This difference might be due to the distinct 
affinities	of	p65/p50	and	p50/p50	NF-kB for the 
two NF-kB-binding sequences (Frankenberger 
and Löms Ziegler-Heitbrock, 1997).
Overall, these results show that lack of 
p21 affects the degree of NF-kB activation 
in macrophages after primary, but not after 
secondary LPS treatment. Absence of p21 
after secondary stimulation disrupts the 
accumulation of p50/p50 homodimers that limit 
the	proinflammatory	responses	of	macrophages	
and attenuate IFN-b expression. p21 therefore 
drives M1 to M2 macrophage reprogramming 
through a mechanism that promotes p50/p50 
NF-kB prevalence and limits IFN-b production.
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in monocytes and studied their response to LPS 
after	 tolerization.	RT-PCR	confirmed	 that	 p21	
mRNA was abolished in p21 siRNA-transfected 
LPS-tolerized monocytes (Figure 32A, upper 
panel).	These	monocytes	showed	a	significant	
increase in IFN-b expression compared 
with control siRNA-transfected cells 
(Figure 32A, lower panel), which indicated that 
p21 downregulation allows IFN-b upregulation 
and halts monocyte hyporesponsiveness. In 
accordance with this observation, impaired 
hyporesponsiveness in p21 knocked-down 
monocytes	was	further	confirmed	by	increased	
production of TNF-a and decreased production 
of	 the	 anti-inflammatory	 cytokine	 IL-10	
(Figure 32B). These data identify p21 as a 
major participant in promoting LPS tolerance 
in human monocytes by limiting both IFN-b 
expression	 and	 their	 overall	 inflammatory	
status.
LPS-tolerant human monocytes 
upregulate p21
The immune response differs substantially 
between mice and humans, and several 
molecules that have a role in LPS tolerance in 
mice are not considered important mediators of 
LPS tolerance in humans (Biswas and Lopez-
Collazo, 2009). Our next objective was therefore 
to	 evaluate	 the	 relevance	 of	 our	 findings	 in	
the human system, and to determine whether 
p21 has a role in LPS tolerance induction 
in human monocytes. To induce tolerance, 
monocytes isolated from healthy volunteers 
were LPS-tolerized (16 h), washed with PBS 
and rechallenged with LPS for various time 
periods (Cubillos-Zapata et al., 2014).  Human 
monocytes showed a notable increase in p21 
expression after LPS tolerization, or tolerization 
and rechallenge (Figure 31A, upper panel). 
IFN-b was downregulated considerably after 
LPS tolerization and rechallenge, compared 
to its strong induction after primary LPS 
activation (Figure 31A, lower panel). Monocyte 
hyporesponsiveness after LPS tolerization 
was	 also	 confirmed,	 as	 indicated	 by	 TNF-a 
downregulation and CCL2 upregulation in LPS-
tolerized cells (Figure 31B). These experiments 
imply that p21 is a critical factor in regulating 
hyporesponsiveness and IFN-b expression in 
human monocytes. LPS tolerization of human 
monocytes has been associated with their 
polarization from an M1 to a M2 tolerant state 
(Porta et al., 2009); our data therefore suggest 
that p21 is a regulator of this reprogramming.
p21 knockdown reverses the LPS-tolerant 
status in human monocytes
To show directly that p21 contributes to 
induction of the hyporesponsive phenotype of 
human monocytes, we performed p21 small 
interfering RNA (siRNA)-silencing experiments 
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FIGURE 31 | Human monocytes upregulate p21 during 
in vitro LPS tolerance. Cultured human monocytes 
isolated from healthy volunteers were tolerized with 
LPS, washed, and restimulated with LPS. (A) RT-PCR 
analysis showing high p21 expression in tolerant human 
monocytes (upper). IFN-b expression was downregulated 
in tolerant cells (lower). (B) LPS-tolerant human 
monocytes	showed	significant	downregulation	of	TNF-a 
and upregulation of CCL2 expression, compared with 
LPS-activated monocytes.  Results were normalized to 
b-actin. Data shown as mean ± SEM (n = 4); *p<0.05; 
**p<0.01; ***p<0.001, one-way ANOVA with Bonferroni 
correction.
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p21 regulates human monocyte 
hyporesponsiveness during sepsis
Monocytes isolated from patients with sepsis 
show an immunosuppressed state and do not 
upregulate	 proinflammatory	 cytokines	 when	
challenged with LPS ex vivo (Faas et al., 2002; 
Escoll et al., 2003), a state that resembles 
LPS	tolerance.	Our	final	objective	was	 to	 test	
whether p21 has a role in the hyporesponsive 
status of monocytes in sepsis.
Monocytes isolated from sepsis patients 
(clinical	details	in	Table	1)	expressed	significantly	
higher p21 levels than healthy volunteers 
(Figure 33A, upper panel). This suggested 
that high p21 expression could control human 
monocyte hyporesponsiveness in sepsis and 
be associated with low IFN-b levels. Monocytes 
from sepsis patients showed an overall low 
IFN-b expression that correlated negatively 
with	p21	expression	in	a	statistically	significant	
manner (Pearson correlation analysis). 
Patients with upregulated p21 had low IFN-b 
levels (Figure 33A, lower panel). Association of 
the hyporesponsive state of patient monocytes 
with low IFN-b expression was validated after 
an LPS challenge, which led to no IFN-b 
upregulation, whereas monocytes from healthy 
volunteers showed notable upregulation of this 
cytokine (Figure 33B, upper panel). p21 levels 
were high in monocytes from sepsis patients, 
and LPS treatment did not further increase 
p21 expression (Figure 33B, lower panel); this 
suggests that the already high p21 levels were 
sufficient	 to	 maintain	 unresponsiveness.	 The	
tolerant phenotype of monocytes in sepsis thus 
appears to be linked to high p21 levels, which 
account for the IFN-b reduction.
Since LPS-tolerant monocytes are 
considered analogous to hyporesponsive 
sepsis monocytes (Biswas and Lopez-Collazo, 
2009), our results thus indicate a role for p21 
in establishing the immunosuppressed state of 
monocytes from sepsis patients.
FIGURE 32 | p21 knockdown reverts the LPS-tolerant status in human monocytes. Cultured human monocytes 
isolated from healthy volunteers were transfected with p21 siRNA or control siRNA. Cells were then LPS-tolerized 
and -rechallenged. (A) After LPS rechallenge, RT-PCR showed abolished p21 mRNA in cultures transfected with 
p21-specific	siRNA	(upper)	and	upregulated	IFN-b expression compared with control siRNA-transfected cells (lower). 
Results were normalized to b-actin. (B) Culture supernatants were analyzed for representative cytokine production by 
ELISA. In p21 siRNA-transfected tolerant human monocytes TNF-a	production	was	significantly	increased	while	IL-10	
production was decreased, compared with control siRNA-transfected monocytes. Data shown as mean ± SEM (n = 4); 
*p<0.05; **p<0.01; ***p<0.001, two-tailed Student’s t test. 
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Age
Cardiac frequency
Respiratory frequency
Temperature
Creatinine
Hematocrit
Leukocytes
Neutrophils
Glucose
K+
Na+
CO3H
Glasgow-CSA
SAPS
Microbiology
Data (n = 7)
68 ± 10.6 years
106.2 ± 3.9 pulsations/min
24.1 ± 1.9 breaths/min
38.4 ± 0.4 °C
2.4 ± 0.3 mg/dl
36.1 ± 3.7
18894.6 ± 3674.9 cells/mm3
15910 ± 3674.9 cells/mm3
134.7 ± 47.7 mg/dl
4.8 ± 0.6 mEq/L
138.5 ± 2.7 mEq/L
17.6 ± 1.2 mmol/L
13.9 ± 0.86
12 ± 1
Gram-negative bacteria
A Glasgow Coma Scale is a neurologic scale that aims to give a 
reliable and objective way to evaluate the neurologic damage in patients.  
Glasgow-CS is part of the APACHE II score.  The normal value of 
Glasgow-CS is 15 (a healthy-normal parameter matched with age).
SAPS, simplified acute physiology score.
TABLE 1 | Clinical parameters.  
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FIGURE 33 | p21 regulates hyporesponsiveness of human monocytes from sepsis patients. (A) Total RNA was 
extracted from monocytes isolated from sepsis patients and healthy volunteers and analyzed by RT-PCR. Upper, p21 
mRNA	levels	were	significantly	higher	in	monocytes	from	sepsis	patients	compared	with	those	from	controls.	Shown	
is median (n = 7); *p<0.05, two-tailed Mann-Whitney U test. Lower, Correlation between p21 and IFN-b levels in 
monocytes from sepsis patients. Results were normalized to b-actin and log2 values were used to calculate correlation; 
n = 7, two-tailed Pearson’s test r = -0.7944, *p<0.05. (B) Monocytes from healthy volunteers and sepsis patients were 
challenged ex vivo with 10 ng/ml LPS (1 h).  RT-PCR analysis showed IFN-b upregulation in monocytes from healthy 
donors but not from sepsis patients (upper).  High p21 expression was detected in monocytes from sepsis patients 
before and after LPS treatment (lower). Results were normalized to b-actin.  Data shown as mean ± SEM (n = 5); 
*p<0.05; **p<0.01; ***p<0.001, two-tailed Student’s t test.
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p21 as a regulator of immune homeostasis
As a small molecule able to participate in a 
number	of	specific	protein-protein	interactions,	
p21 has an essential role in the regulation of 
many biological functions such as cell cycle, 
apoptosis, cell differentiation and senescence, 
oxidative stress, and gene expression (Dotto, 
2000). Ever since the initial discovery that p21-
deficient	mice	develop	 lupus-like	autoimmune	
disease (Balomenos et al., 2000), interest 
in p21-dependent regulation of immune 
responses has not abated. In the absence of 
p21, T cells hyperproliferate, leading to break 
of tolerance (Balomenos et al., 2000). p21 
does not affect naïve T cells, but exclusively 
regulates the proliferation of effector/memory T 
cells that survive AICD (Arias et al., 2007). This 
property of p21 has a therapeutic effect, since 
p21 transgenic overexpression in T cells of B6/
lpr mice prone to lupus-like disease reduced 
proliferation and activation of autoreactive T 
cells and ameliorated the disease (Daszkiewicz 
et al., 2015). In addition, reports from our 
laboratory and others demonstrated a role for 
p21 in regulation of innate immunity. In the 
absence of p21, macrophages show increased 
NF-kB	 activity	 and	 proinflammatory	 cytokine	
production in response to LPS, rendering the 
p21-/- mice extremely sensitive to septic shock 
(Trakala et al., 2009; Scatizzi et al., 2009). 
Furthermore, a p21 mimetic peptide had a 
therapeutic effect on macrophage activation 
during	 experimental	 inflammatory	 arthritis	
(Mavers et al., 2012).
These reports clearly link p21 with regulation 
of both innate and adaptive immune responses. 
The mechanism by which p21 regulates T 
cells and macrophages, as well as its impact 
on human patients, nonetheless remained 
unexplained. In this study, we establish that 1) 
p21 controls the activation of effector/memory 
T cells and their IFN-g production by regulating 
mROS	 production,	 2)	 p21	 deficiency	 in	 LPS-
activated macrophages leads to enhanced 
mROS production and DNA binding of p65/
p50 NF-kB, and 3) p21 promotes macrophage 
reprogramming during LPS tolerance by 
regulating the balance between active p65/p50 
and inhibitory p50/p50 NF-kB, which is relevant 
in human sepsis; p21 might thus be a target 
molecule for sepsis treatment.
p21 regulates IFN-g production in effector/
memory CD4+ T cells through NF-kB
In B6/lpr mice, effector/memory T cells 
hyperproliferate and are hyperactivated, 
leading to development of lupus-like 
autoimmune disease (Balomenos et al., 1997; 
Fortner and Budd, 2005). We explored the p21 
therapeutic effect by increasing its expression 
in B6/lpr mice. In addition to controlling T cell 
proliferation (Daszkiewicz et al., 2015), p21 
transgenic expression reduced B6/lpr effector/
memory T cell activation and the proportion of 
IFN-g-secreting cells (Figures 1 to 3). These data 
suggest that overexpressed p21 has functions 
in T cell response control other than cell cycle 
inhibition. Overexpressed p21 did not affect 
the effector/memory T cell population of normal 
background B6-p21tg mice (Figures 1 and 2), 
indicating	that	endogenous	p21	is	sufficient	to	
control normal T cell responses, whereas high 
p21 levels are needed to control autoimmune 
lpr T cells. In vitro study validated these results, 
and showed that after primary TCR stimulation 
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and IL-2 expansion, direct IFN-g induction by 
IL-12	and	IL-18	is	significantly	inhibited	by	the	
p21 transgene (Figure 3). This implied that p21 
directly controls the IFN-g induction pathway. 
Indeed,	p21	deficiency	 in	B6/lpr and B6 (WT) 
effector/memory T cells leads to increased 
IFN-g induction by IL-12 and IL-18 (Figures 5 
and 6). In addition, by reducing IFN-g production 
in effector/memory T cells, the p21 transgene 
exerts a paracrine effect on macrophages, 
since the differential IFN-g levels secreted by 
B6/lpr and B6/lpr-p21tg T cells greatly reduced 
macrophage	 activation	 and	 inflammatory	
potential (Figure 4).
In the absence of p21, effector/memory 
T cells produced elevated IFN-g levels in 
response to stimulation with a combination 
of IL-12 and IL-18, but not with IL-12 alone 
(Figure 6). This suggested that p21 might 
control only IL-18-dependent IFN-g induction. 
To verify this, we examined the activation of 
p-STAT4 and NF-kB, which are dependent 
on IL-12 and IL-18, respectively (Robinson et 
al., 1997; Nakahira et al., 2002). Contrary to 
our predictions, we found elevated activation 
of both STAT4 and NF-kB in p21-/- effector/
memory T cells after IL-12/IL-18 stimulation 
(Figure 7). High activation of NF-kB and/or 
IFN-g as induced by IL-18 could contribute to 
an increase in IL-12 receptor expression and 
consequently, STAT4 phosphorylation (Aita et 
al., 2004; Wu et al., 2000). We therefore suggest 
that lack of p21 enhances IFN-g production in 
effector/memory CD4+ T cells through its effect 
on IL-18-dependent NF-kB activation.
p21 regulates TCR-dependent and 
-independent effector/memory CD4+ T cell 
activation through mitochondrial reactive 
oxygen species
Naïve, activated and memory T cells have 
different	 metabolic	 profiles	 (Ron-Harel	 et	 al.,	
2014). Sena et al. recently demonstrated a 
central role in signaling for mROS after an-
tigen-specific	 T	 cell	 activation	 (Sena	 et	 al.,	
2013). In this study, mice with conditional dele-
tion of the mitochondrial complex III subunit in 
T cells have decreased proportions of activat-
ed CD44hiCD62Llo T cells, which show reduced 
IFN-g production (Sena et al., 2013). Our study 
shows that p21 negatively regulates mROS 
production in effector/memory T cells, during 
both TCR- and IL-12/IL-18-dependent stimula-
tion (Figures 8 and 9). Using DPI (diphenylene-
iodonium), an inhibitor of mitochondrial com-
plexes I and II, we demonstrated that mROS 
is necessary for IFN-g production in effector/
memory	T	cells	(Figure	10).	In	confirmation	of	
TCR IL-12R IL-18R
mROS p21
NF-κB
TLR4
SCHEME 7 | p21 is a negative regulator 
of mitochondrial ROS. Through its effect 
on mitochondrial ROS, p21 regulates TCR-
dependent and -independent T cell activation, 
as well as macrophage TLR4 activation, 
acting	 as	 a	 suppressor	 of	 inflammatory	 and	
autoimmune syndromes. 
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these data, mROS inhibition strongly reduced 
p65 phosphorylation in p21-/- effector/memory 
T cells (Figure 13), which suggests that p21 
negatively regulates NF-kB-dependent IFN-g 
production through mROS (Scheme 7). Our 
results also showed that mROS is needed for 
CD44hi memory T cell generation (Figure 11). 
This	finding	could	explain	the	fact	that	p21	de-
ficiency	leads	to	increased	generation	of	effec-
tor/memory CD44hiCD62Llo T cells (Figure 6). 
p21 regulates mitochondrial reactive 
oxygen species production in 
macrophages
Mitochondrial reactive oxygen species 
(mROS) have long been considered harmful 
by-products of metabolism that damage 
cellular lipids, proteins and nucleic acids 
(Finkel and Holbrook, 2000). In the last decade, 
however, it has become evident that ROS are 
also crucial in cell signaling, in both innate 
and adaptive immunity. West et al. reported 
that TLR4 activation in macrophages leads to 
increased mROS production, which is needed 
for bacterial clearance (West et al., 2011a). In 
addition, cells from TRAPS (tumor necrosis 
factor receptor-associated periodic syndrome) 
patients show elevated LPS responsiveness 
due to increased mROS production (Bulua 
et al., 2011). Previous reports, including 
data	 from	 our	 laboratory,	 identified	 p21	 as	
a negative regulator of NF-kB activity and 
proinflammatory	 cytokine	 production	 in	 LPS-
activated macrophages (Trakala et al., 2009; 
Scatizzi et al., 2009). Increasing evidence 
indicates that mitochondrial ROS (mROS) can 
facilitate	pro-inflammatory	cytokine	production	
through redox-sensitive activation of IKK 
complex and NF-kB (Bai et al., 2005; Gloire 
et al., 2006; West et al., 2011b); we therefore 
investigated whether p21 controls mROS in 
macrophages following LPS stimulation. At 
early times post-LPS stimulation, we found 
significantly	 increased	 mROS	 and	 cellular	
ROS in p21-/- mouse macrophages compared 
to those from WT mice (Figure 15). Lack of p21 
did not affect MAPK or MyD88-independent 
pathways, indicating a role for p21 in negative 
regulation of TLR4 signaling through mROS 
(Scheme 7).
p21 promotes macrophage M1 to M2 
reprogramming during LPS tolerance
Due to their plasticity, macrophages can 
polarize from an M1 to an M2 phenotype 
(Mosser and Edwards, 2008; Mills, 2012; Sica 
and Mantovani, 2012) or undergo functional 
reprogramming	 from	 an	 inflammatory	 to	
a hyporesponsive state (Shalova et al., 
2015), while maintaining alternative function 
(Pena et al., 2011). Immunosuppressed 
monocytes and macrophages have been 
described in pathologies such as sepsis, 
acute coronary syndrome, and cystic 
fibrosis	 (Pena	 et	 al.,	 2014;	 Fernández-Ruiz	
et al., 2014; del Fresno et al., 2008). During 
sepsis development, macrophages undergo 
an	 intense	 proinflammatory	 response	
and also acquire a hyporesponsive state. 
Patient mortality is associated mainly to the 
immunosuppressed phase rather than to the 
inflammatory	 stage.	 Independently	 of	 its	 cell	
cycle inhibitory role, p21 inhibits LPS-induced 
proinflammatory	 macrophage	 activation	 and	
septic shock development (Trakala et al., 
2009; Scatizzi et al., 2009). Here, we explored 
whether p21 might affect sepsis by controlling 
inflammatory	 macrophage	 reprogramming	
to a hyporesponsive phenotype. Since this 
hyporesponsive state resembles macrophage 
immunosuppression after LPS tolerization 
(Porta et al., 2009), we used this model 
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to study the role of p21 in the induction of 
hyporesponsiveness. LPS tolerance results 
in	 reprogramming	 of	 inflammatory	M1	 to	M2-
like macrophages that display a tolerant status 
after LPS rechallenge (Porta et al., 2009; 
Pena et al., 2011). We examined whether p21 
affects the ability of macrophages to adopt a 
hyporesponsive phenotype and/or polarize 
to an M2 phenotype. Lack of p21 disrupted 
LPS macrophage tolerization, both in vitro 
and in vivo, and attenuated M1 macrophage 
reprogramming to an M2 hyporesponsive state. 
Analysis of this p21 effect led to three central 
conclusions. First, p21 promotes macrophage 
reprogramming to a hyporesponsive state by 
downregulating IFN-b. Second, p21 emerges 
as a regulator of the p65/p50 and p50/p50 
NF-kB balance by promoting the accumulation 
of inhibitory p50/p50 complexes, which bind 
to the IFN-b promoter and downregulate 
IFN-b expression. Finally, p21 also governed 
human monocyte responses, as p21 silencing 
in these cells augmented IFN-b production 
and restricted LPS tolerization. These results 
support a system in which p21 upregulation 
and IFN-b downmodulation could contribute to 
hyporesponsiveness induction in monocytes 
from sepsis patients.
p21 deficiency impairs LPS tolerance
p21-/- mice do not develop tolerance after 
LPS priming and rechallenge, and die due 
to increased TNF-a and IFN-b production 
compared with WT mice. In the peritoneal 
cavity of p21-/- mice, we detected increased 
activation of M1-like F4/80lo macrophages 
(Ghosn et al., 2010; Ní Gabhann et al., 
2014; Singh et al., 2015). Since M1 to M2 
macrophage reprogramming is considered 
essential for in vivo LPS tolerance (Pena et al., 
2011; Porta et al., 2009), our result suggested 
that compromised tolerance could be a result of 
failed M1 to M2 polarization. M2 macrophages, 
generated from M1 during LPS tolerance, are 
distinct from the conventional IL-4-dependent, 
alternatively activated M2 macrophages, which 
are not implicated in LPS tolerance (Rajaiah et 
al., 2013).
During in vitro LPS tolerization and 
rechallenge (Porta et al., 2009), p21-/- 
macrophages showed decreased expression 
of M2 markers compared with WT mice 
(Figure	 23),	 while	 producing	 significantly	
higher levels the M1-associated cytokines 
TNF-a and IL-1b. Although TNF-a levels were 
clearly reduced after tolerization in both WT 
and p21-/- macrophages, IFN-b remained high 
after tolerization and prior to rechallenge only 
in the p21-/- macrophages. These persistent 
IFN-b levels, even in the absence of LPS 
stimulus, suggested that the p21 effect on IFN-b 
expression levels is of particular importance in 
tolerance induction. Concurring with this idea, 
IFN-b has been proposed to attenuate LPS 
tolerization, since it is expressed strongly in 
p50-/- macrophages, which fail to develop LPS 
tolerance (Porta et al., 2009).
p21-dependent IFN-b downregulation is 
crucial for development of LPS tolerance
During	primary	LPS	treatment,	p21	deficiency	
led to increased IFN-b production (Figure 17), 
although this did not translate into increased 
IFN-dependent gene expression, since IFN-b 
production	in	WT	cells	was	sufficient	to	induce	
saturating IFNAR activation. In contrast, during 
LPS tolerization, WT cells downregulated 
IFN-b expression, while p21-/- cells produced 
significantly	 higher	 IFN-b levels (Figure 23), 
which led to increased STAT1 phosphorylation 
and IFN-b-dependent gene expression after 
LPS rechallenge (Figure 25). High IFN-b levels 
produced during primary LPS activation must 
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thus be effectively downregulated for tolerance 
to occur; otherwise, sustained IFN-b autocrine 
stimulation	 maintains	 M1	 proinflammatory	
status, obstructing tolerance. Since p21-/- 
macrophages produce high IFN-b  levels after 
LPS tolerization and do not undergo M1 to M2 
polarization, we considered that anti-IFN-b 
antibody treatment could enable tolerance 
development in the absence of p21. IFN-b 
neutralization during LPS tolerization allowed 
p21-/- macrophages to reach a hyporesponsive 
state like that of WT cells, with decreased M1 
activation characteristics (Figure 26). Even 
when IFN-b was neutralized during LPS 
rechallenge, p21-/- macrophage responses 
such as STAT1 phosphorylation and iNOS 
induction were reduced. Increased IFN-b 
therefore appears to impair tolerance of p21-/- 
macrophages, which can be reestablished 
when IFN-b is blocked. This was further 
validated in an in vivo setting of LPS tolerance, 
in which neutralization of IFN-a/b receptor 
prior to LPS rechallenge radically improved the 
survival of p21-/- mice. These data indicate that 
p21 promotes macrophage reprogramming 
from	 a	 proinflammatory	 to	 a	 hyporesponsive	
state by downmodulating IFN-b production.
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SCHEME 8 | Model showing dual role of p21 in regulating macrophage activation and LPS tolerance. During 
primary LPS activation, p21 suppresses the NF-kB	activation	pathway	thus	controlling	proiflammatory	cytokine	and	
IFN-b production. After prolonged or repeated LPS stimulation, p21 controls the development of tolerance by promoting 
inhibitory NF-kB complex and the immunosuppression of LPS tolerant M2 macrophages. 
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p21 regulates the balance between p65/p50 
and p50/p50 NF-kB during LPS tolerance
As p21 negatively regulates NF-kB 
activation after primary LPS challenge (Trakala 
et al., 2009), we considered that p21 could 
also modulate this activation in rechallenged 
macrophages, and thus suppress M1 to M2 
transition. In contrast to our predictions, p21-/- 
and WT macrophages showed similar NF-kB 
DNA binding activity after LPS rechallenge. 
Our	data	nonetheless	identified	a	role	for	p21	in	
regulating the balance between active p65/50 
and inhibitory p50/50 NF-kB dimers.
Accumulation of p50/p50 NF-kB was 
originally proposed to drive macrophage 
immunosuppression (Ziegler-Heitbrock, 2001); 
accordingly, p50-/- murine macrophages failed 
to develop LPS tolerance (Wysocka et al., 
2001; Bohuslav et al., 1998). Furthermore, 
LPS tolerance, which induces M1 to M2 
macrophage reprogramming, is driven by 
the increase of inhibitory p50/p50 over p65/
p50 NF-kB dimers (Porta et al., 2009). In 
our system, lack of p21 impaired M1 to M2 
macrophage reprogramming by sustaining low 
p50/p50 levels and a predomination of p65/p50 
complexes. After secondary LPS stimulation, 
p21-/- macrophages showed a notable 
alteration of the relative expression pattern of 
p65/p50 vs. p50/p50 products bound to the 
NF-kB consensus sequence, with a reduction 
in p50/p50 bound complexes (Figure 30). 
This reduction accounted for the increased 
production of NF-kB consensus sequence-
dependent products such as TNF-a. We further 
showed that after primary LPS stimulation, in 
which p21 regulates overall NF-kB activation, it 
also regulates the balance of p65/p50 and p50/
p50 complexes later in the activation process 
(Figure 19). p21 thus has a dual role in NF-kB 
regulation; on the one hand, it suppresses 
the NF-kB activation pathway after LPS 
stimulation, and on the other, blunts NF-kB 
activity by promoting inhibitory NF-kB complex 
and immunosuppression of LPS-tolerant M2 
macrophages (Scheme 8).
To	 determine	 how	 p21	 deficiency	 drives	
IFN-b through regulation of the NF-kB 
complex, we examined the relative binding 
of p65/p50 vs. p50/p50 NF-kB	 to	 a	 specific	
IFN-b promoter sequence that differs from the 
NF-kB consensus sequence (Garoufalis et al., 
1994). We detected remarkably increased p65/
p50 binding to the IFN-b promoter sequence 
in p21-/- compared to WT LPS-rechallenged 
macrophages, while p50/50 binding was 
proportionally	 decreased.	 This	 result	 justified	
the increase in IFN-b by LPS-rechallenged 
p21-/-	macrophages,	and	confirmed	the	role	of	
p21 as a modulator of IFN-b production. In the 
absence of p21, the IFN-b promoter sequence 
showed higher p65/p50 and lower p50/p50 
binding compared to the NF-kB consensus 
sequence.	This	finding	could	be	explained	by	
the	 fact	 that	 p65/p50	 has	 greater	 affinity	 for	
the IFN-b promoter than for the consensus 
sequence, while the opposite is the case for 
p50/p50 (Frankenberger and Löms Ziegler-
Heitbrock, 1997). Overall, these data indicate 
that	p21	deficiency	shifts	the	p65/p50	and	p50/
p50 balance toward the active p65/p50 NF-kB 
complexes, and that IFN-b expression is more 
susceptible to this p21 effect.
p50/p50 NF-kB accumulation during LPS 
tolerance depends on p65/p50 activation 
(Ziegler-Heitbrock, 2001). Our data, which show 
similar NF-kB pathway activation in both WT 
and p21-/- macrophages after LPS rechallenge, 
do not support upregulation of p50/p50 driven 
by p21-dependent p65/p50 accumulation. 
IL-10-dependent p50 stabilization by BCL-3 
(Wessells et al., 2004; Carmody et al., 2007; 
Kuwata et al., 2003) might nonetheless be 
related to the p21 role as an enhancer of p50/50, 
since	our	results	associate	p21	deficiency	with	
IL-10	downregulation	(Figure	24).	Our	findings	
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showing that p21 modulates the p65/p50 and 
p50/p50 balance provide a clear advance in 
understanding this complex NF-kB regulation 
process.
p21 promotes LPS tolerance in human 
monocytes
Mechanisms that drive macrophage 
unresponsiveness differ between human 
and mouse models, and several molecules 
reported as mediators of LPS tolerance in mice 
(such as SHIP, SOCS1 and A20) (Sly et al., 
2004; Liew et al., 2005) are not upregulated 
during hyporesponsiveness in humans (Del 
Fresno et al., 2009; Van ’t Veer et al., 2007). It 
was therefore essential to verify whether p21 
expression downregulates IFN-b expression 
and induces M2 hyporesponsiveness in 
human monocytes. After LPS tolerization 
and rechallenge, human monocytes showed 
increased p21 levels, which lowered IFN-b 
expression (Figure 31). This p21 function 
was validated directly, since p21 knockdown 
reverted the hyporesponsive phenotype of LPS-
tolerized human monocytes, which had high 
IFN-b levels (Figure 32). In accordance with 
the analogous state between LPS tolerance 
and monocyte hyporesponsiveness in sepsis 
(Shalova et al., 2015), p21 was strongly 
upregulated in refractory patient-derived 
monocytes, while IFN-b was downmodulated 
(Figure 33). Statistical analysis showed a 
significant	 negative	 correlation	 between	 p21	
and IFN-b levels. These data support the 
biological importance of our work and suggest 
that by reducing IFN-b levels, p21 is a key factor 
in driving macrophage hyporesponsiveness in 
human disease.
Although the IFN-b requirement has been 
established in viral infection, its role in bacterial 
infection	 is	 not	 clearly	 defined	 (McNab	 et	
al.,	 2015).	 In	 addition	 to	 its	 proinflammatory	
effect, an immunosuppressive role is also 
attributed to IFN-b (Yoo et al., 2014). The 
complex properties of this cytokine have been 
pointed	out	for	 inflammation	and	septic	shock	
(Trinchieri, 2010).
Septic shock induction in mice requires 
IFN-b, as shown by studies with IFN-b  and 
IFN-b receptor (IFNAR) knockout mice 
(Karaghiosoff et al., 2003; Huys et al., 2009), 
as well as other mouse models that regulate 
IFN-b expression (Mahieu and Libert, 2007; 
Mahieu et al., 2006). On the basis of these 
results, IFN-b targeting in human sepsis 
was proposed to have therapeutic potential 
(Mahieu and Libert, 2007). In contrast to its 
proinflammatory	 role,	 it	 is	 thought	 that	 IFN-b 
might trigger monocyte immunosuppression 
in sepsis or endotoxin tolerance (Biswas and 
Tergaonkar, 2007); in fact, recent experiments 
showed that IFN-b delivery severely reduces 
septic shock development in mice (Yoo et 
al., 2014). Due to the contrasting effects of 
IFN-b, the concept of limiting its signaling 
for therapeutic purposes entails conceptual 
difficulties.	Our	 results,	which	 show	 that	 p21-
dependent IFN-b  downmodulation drives 
monocyte hyporesponsiveness, discourage 
the use of IFN-b reduction-based treatment in 
sepsis, as it could further deteriorate responses 
to secondary infections.
Here	we	 identified	a	role	 for	p21	 in	driving	
mouse and human M1 to M2 macrophage/
monocyte reprogramming, and established 
that upregulated p21 results in IFN-b 
downregulation and hyporesponsiveness in 
these	cells.	These	findings	link	to	our	data	from	
hyporesponsive monocytes of sepsis patients, 
which also showed increased p21 expression 
that correlated negatively with IFN-b levels. 
p21-driven IFN-b downregulation is therefore 
essential for induction of hyporesponsiveness 
in monocytes and macrophages. p21 
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modulates the p50/p50 and p65/50 NF-kB 
balance, allowing accumulation of inhibitory 
p50/p50 complexes that ultimately attenuate 
IFN-b production. These data demonstrate 
a	 role	 for	 p21	 in	 fine-tuning	 the	 balance	 of	
NF-kB products and in promoting macrophage 
hyporesponsineness. This function differs 
distinct from its previously described role as 
a suppressor of the NF-kB activation pathway 
after macrophage stimulation. p21 is thus a 
major factor in potentiating p50-driven control of 
inflammation	and	a	key	molecule	in	regulating	
macrophage	transition	from	a	proinflammatory	
to a hyporesponsive state. Since regulation of 
this transition could be of therapeutic value for 
sepsis treatment, understanding this role of 
p21	could	assist	in	defining	molecular	aspects	
of monocyte reprogramming and in discovering 
new targets for sepsis treatment.
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CONCLUSIONS
1. In addition to controlling effector/memory T cell proliferation, p21 negatively regulates their 
activation and IFN-g production. This role of p21 is physiologically relevant, since T cell-directed 
p21 overexpression reduces autoimmune disease manifestations in lpr mice by reducing IFN-g 
production	in	effector/memory	T	cells.	Conversely,	p21	deficiency	increases	IFN-g production in 
T cells from lpr mice.
2. p21 negatively regulates the production of mitochondrial reactive oxygen species (mROS) in 
effector/memory T cells, after both TCR-dependent and -independent stimulation. Through 
negative regulation of mROS, p21 controls NF-kB activation and IFN-g production, as well as 
effector/memory T cell generation.
3. In macrophages, p21 acts as a negative regulator of TLR4 signaling through mROS and NF-kB, 
without affecting MAPK or MyD88-independent pathways. In addition to controlling overall 
NF-kB activity, p21 inhibits DNA binding of active p65/p50 NF-kB. 
4. p21 is a key regulator of M1 to M2 macrophage reprogramming during LPS tolerance.
5. In LPS-tolerized macrophages, p21 promotes development of tolerance through IFN-b 
downregulation. This role of p21 has physiological relevance, since IFN-b-neutralization in p21-
deficient	mice	improves	survival	following	dual	LPS	challenge.
6. During LPS tolerance, p21 does not affect overall NF-kB activity; rather, it controls the balance 
between active p65/p50 and inhibitory p50/p50 NF-kB, by promoting accumulation of p50/p50 
homodimers, which drive tolerance.
7. p21 drives LPS tolerance in human monocytes; it is upregulated in monocytes from sepsis 
patients, where it correlates negatively with IFN-b and might thus have therapeutic relevance.
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La	 proteína	 p21	 participa	 en	 gran	 número	
de interacciones biológicas, entre las cuales 
se encuentra la regulación de muchos 
procesos celulares tales como la apoptosis, 
la diferenciación celular, el envejecimiento, el 
ciclo celular, el estrés oxidativo y expresión 
génica (Dotto, 2000). Su papel en las patologías 
autoinmunes se describió inicialmente al 
identificar	una	enfermedad	autoinmune	similar	
al lupus en ratones que carecían de este gen 
(Balomenos et al., 2000). Desde entonces 
nuestro grupo se ha centrado en descifrar su 
papel en la regulación de la respuesta inmune. 
Inicialmente	se	 identificó	que	su	ausencia,	
conduce a una hiperproliferación de linfocitos T 
que se relaciona con una perdida de tolerancia 
(Balomenos et al., 2000). Sin embargo, p21 
no afecta a los linfocitos T naive, pero regula 
exclusivamente la proliferación de linfocitos 
de memoria y efectores que sobrevivieron 
a AICD (Arias et al., 2007). Recientemente 
demostramos que esta propiedad de p21 tiene 
un efecto terapéutico, su sobreexpresión en 
linfocitos T de ratones B6/lpr con predisposicion 
para lupus redujo la proliferación y activación 
de linfocitos T autoreactivos y disminuyendo 
la gravedad de la enfermedad (Daszkiewicz et 
al., 2015). 
Varios estudios incluyendo datos de 
nuestro grupo, demuestran que p21 participa 
en la regulación de la inmunidad innata. En 
su ausencia, los macrófagos muestran un 
incremento en la actividad de NF-kB y de 
producción de citoquinas en respuesta a LPS, 
haciendo los ratones p21-/- extremadamente 
sensible al shock séptico (Trakala et al., 2009; 
Scatizzi et al., 2009). En modelos de artritis 
inflamatoria	 la	 administración	 de	 un	 peptido	
similar a p21 tuvo un efecto terapéutico (Mavers 
et al., 2012); con estos hallazgos se relaciona 
a p21 en la regulación tanto con la inmunidad 
innata como con la adquirida. No obstante, no 
se ha descrito como es el mecanismo por el 
cual p21 regula la actividad de macrófagos y 
linfocitos T y su comportamiento en humanos:
Para nuestro estudio se establecieron los 
siguientes objetivos:
1. Investigar si el papel de p21 
en la regulación de la activación de los 
linfocitos T CD4+ de memoria y efectores 
es	 fisiopatológicamente	 relevante	 en	 el	
desarrollo de autoinmunidad.
2. Investigar si p21 regula 
directamente la producción de IFN-g en 
linfocitos T CD4+ de memoria y efectores.
3. Obtener un modelo explicativo 
de cómo p21 controla la activación de 
linfocitos CD4+ de memoria y efectores junto 
con la producción de IFN-g.
4.  Estudiar el comportamiento 
de p21 en la activación de macrófagos 
dependiente de TLR4. 
5. Investigar si p21, como un 
regulador negativo de la activación de TLR4, 
afecta la reprogramación de los macrófagos 
durante la tolerancia con LPS.
6. Identificar	 el	 mecanismo	 de	
cómo p21 regula la reprogramación durante 
la tolerancia de LPS.
7. Relacionar si los hallazgos 
obtenidos con p21 en la reprogramación 
de macrófagos durante la tolerancia con 
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LPS son relevantes en humanos durante 
procesos sépticos.
El reconocimiento de lo propio de lo no 
propio es una propiedad del sistema inmune 
que permite vivir en armonía con nuestras 
células y tejidos sin desarrollar enfermedades 
autoinmunes. Los ratones que tienen la 
mutación lpr desarrollan linfadenopatia y 
una enfermadad similar al lupus debido a la 
hiperactivación y proliferación de linfocitos 
T CD4+, además, muestran acumulación de 
linfocitos T memoria y efectores los cuales 
producen grandes cantidades en IFN-g, siendo 
esta una citoquina clave en el lupus. Estudios 
previos	 de	 nuestro	 grupo	 identificaron	 que	
p21 disminuye la autonimunidad al limitar la 
proliferación de los linfocitos T. Para investigar 
el efecto terapéutico de p21 en el lupus, sobre 
expresamos p21 en linfocitos T de ratones lpr. 
Como esperábamos la sobreexpresión de p21 
redujo la expansión de linfocitos T memoria 
y efectores y síntomas de autoinmunidad. 
Nuestros resultados demuestran la capacidad 
de p21 para disminuir la producción de IFN-g 
y la activación de linfocitos T. Estudios in vitro 
validan estos resultados, mostrando que la 
estimulación primaria de TCR, la expansión de 
IL-2, la inducción directa de IFN-g por IL-12 y 
IL-18	 fue	 inhibida	 significativamente	 por	 p21	
transgénico.	 Por	 el	 contrario,	 la	 deficiencia	
de p21 aumenta la producción de IFN-g en 
linfocitos T de memoria y efectores cuando 
son estimulados por IL-12 y IL-18, sugiriendo 
que p21 controla directamente la inducción de 
IFN-g. En efecto, nuestros datos revelan que 
p21 controla inducción IFN-g  dependiente 
la estimulacion de IL-18 en linfocitos T de 
memoria y efectores a través de la regulación 
negativa de la actividad de NF-kB.
 En la inmunidad contra patógenos 
intracelulares las especies reactivas de oxigeno 
(ROS) desempeñan un papel fundamental 
en el control de la infección y eliminación de 
microorganismos. Recientes estudios sugieren 
que los ROS en la mitocondria participan 
activamente en vías de señalización, tales 
como la activación de linfocitos T dependiente 
de TCR y activación de macrófagos vía TLR4. 
Por lo tanto encontramos que p21 controla la 
producción de ROS a nivel mitocondrial en 
los linfocitos efectores y de memoria cuando 
son estimulados via TCR e IL-12/IL-18. Este 
efecto de p21 es importante para la producción 
de IFN-g, como inhibidor de ROS a nivel 
mitocondrial reduce de manera importante la 
activación de NF-kB y la producción de IFN-g. 
Además la inhibición a nivel mitocondrial 
de ROS conduce a una disminución de la 
proliferación de linfocitos T de memoria y 
efectores. Estos datos exponen que la función 
de los linfocitos T de memoria y efectores 
está determinada de manera importante por 
los	 ROS	 a	 nivel	 mitocondrial	 e	 identificar	 a	
p21 como un regulador de la actividad tanto 
independiente como dependiente de TCR 
a través de los ROS a nivel mitocondrial. 
La información previa de nuestro grupo 
revelo que p21 regula de manera negativa la 
activación de NF-kB en macrófagos activados 
con	LPS.	Hasta	aquí	podemos	identificar	que	
p21 regula negativamente la producción de 
ROS en las mitocondrias cuando se estimulan 
los macrófagos con LPS. La carencia de p21 
no afecta las vías de MAPK o MyD88, lo que 
indicaría que el papel de p21 en la regulación 
negativa of TLR4 es dependiente de la 
señalización por los ROS a nivel mitocondrial.
Los macrófagos pueden diferenciarse 
en dos fenotipos diferentes con funciones 
opuestas, están los que se activan de forma 
clásica	 (M1	 o	 inflamatorios)	 y	 activados	 de	
manera	 alternativa	 (antiinflamatorios	 o	 M2).	
La plasticidad de los macrófagos es una 
propiedad extraordinaria, la cual le permite 
diferenciarse de fenotipo M1 a M2. En la sepsis, 
una causa importante de mortalidad, después 
de	una	 intensa	 respuesta	proinflamatoria,	 los	
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macrófagos M1 sufren una reprogramación 
funcional	 y	 adquieren	 un	 perfil	 de	 similar	 a	
su estado M2. Es importante destacar que la 
mortalidad está principalmente asociada con la 
fase de inmunosupresión debido al incremento 
de riesgo de infecciones secundarias. Los 
mecanismos moleculares subyacentes en la 
reprogramación de los macrófagos en sepsis 
no se han estudiado completamente, tal ves 
en estos mecanismos se encuentren nuevos 
avances terapéuticos. La reprogramación 
desde el fenotipo M1 a M2 puede ser simulada 
con la estimulacion repetida y prolongada 
con LPS cuando los macrófagos sufren 
tolerancia.	 Identificamos	 que	 p21	 participa	
en la diferenciación de macrófagos de M1 a 
M2, independientemente de su papel como 
inhibidor del ciclo celular. La carencia en ratones 
de p21 no desarrollan tolerancia después 
la exposición repetida con LPS y mueren 
en relación a un incremento de mediadores 
asociados al fenotipo de macrófagos M1 
e IFN-b . Los macrófagos p21-/- muestran 
alteraciones en la formación de homodimero 
p50/p50 NF-kB y su capacidad para regular 
la disminución de la producción de IFN-b  y 
adquiere un estado de M2. Estos resultados 
revelan el papel fundamental en al regulación 
de IFN-b en procesos de inmunosupresión. 
En efecto, la neutralización de IFN-b permite 
a los macrófagos p21-/- alcanzar un estado de 
hiporespuesta al impedir su diferenciación a su 
fenotipo M1. Así, por medio de la regulación 
del balance entre su estado activo p65/p50 
e inhibitorio p50/p50 NF-kB p21 favorece la 
acumulación de complejos p50/p50, los cuales 
se unen al promotor de IFN-b y disminuye su 
expresión. Los mecanismos que conducen a 
la	hiporreactividad	de	 los	macrófagos	difieren	
entre los modelos animales y humanos, 
por lo que es importante investigar si p21 
afecta su diferenciación en humanos. In vitro 
la inducción de la tolerancia con LPS en 
monocitos	humanos	conduce	a	un	significante	
incremento de la expresión de p21 lo que se 
relaciona	 con	 un	 perfil	 de	 diferenciación	 de	
estado M2 y disminución de la producción de 
IFN-b. Por el contrario en células donde se 
inhibe la expresión génica de p21 se revierte 
su estado de M2 y presentan incrementos 
de marcadores de fenotipo M1 y producion 
de IFN-b.  Estos	 hallazgos	 confirma	 el	 papel	
de p21 en la diferenciación en monocitos 
humanos.	También	se	ha	 identificado	que	en	
monocitos humanos de pacientes con sepsis, 
los cuales fueron extraidos en un estado de 
hiporespuesta, muestran un incremento en la 
expresión de p21 comparado con monocitos 
aislados	 de	 voluntarios	 sanos.	 Identificamos	
también una correlación negativa entre la 
expresión de p21 e IFN-b en pacientes con 
sepsis	 lo	cual	soporta	el	significado	biológico	
de nuestro trabajo y sugiere que p21 es un 
factor substancial en la hiporreactivadad de los 
macrófagos en patologías humanas al reducir 
la expresión de IFN-b. En general toda esta 
información permite intuir un mecanismo de 
inmunosupresión de monocitos/macrófagos, 
a partir de la regulación de p21 del balance 
entre p50/p50 y p65/50 NF-kB favoreciendo la 
acumulación del dímero p50/p50  que induce 
la disminución de la producción de IFN-b y 
en consecuencia hiporreactividad. Por ultimo 
nuestros hallazgos designa a p21 como un 
regulador de la diferenciación de macrófagos 
en sepsis y como una posible diana terapéutica. 
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CONCLUSIONES
1. Ademas de controlar la proliferación de linfocitos T de memoria y efectores, p21 regula 
negativamente su activación y producción de IFN-g.	Esta	función	de	p21	es	fisiológicamente	
importante, en razón de que su sobreexpresión se relaciona con la disminución de la gravedad 
de las enfermedades autoinmunes en ratones lpr al reducir la producción de IFN-g en linfocitos 
T	de	memoria	y	efectores.	Por	el	contrario,	la	deficiencia	de	p21	incrementa	la	producción	de	
IFN-g en linfocitos T de ratones lpr. 
2. A nivel mitocondrial en los linfocitos T de memoria y efectores la producción de especies 
reactivas de oxigeno (mROS) es regulado negativamente por p21, tanto de manera dependiente 
como independiente de la estimulación de TCR. A través de la regulación negativa de mROS, 
p21 controla la activación de NF-kB, la producción de IFN-g, y la generación de linfocitos T de 
memoria y efectores. 
3. En macrófagos, p21 participa como un regulador negativo de TLR4 realizando la señalización 
por medio de mROS y NF-kB, sin involucrar las vías de MAPK o MyD88. Además p21 controla 
actividad de NF-kB e inhibe la unión de p65/p50 NF-kB al DNA.
4. p21 es un regulador fundamental en la reprogramación de macrófagos de fenotipo M1 a M2.
5. En los macrófagos que se ha inducido tolerancia con LPS, p21 inhibe la expresión de IFN-b. 
Esta	función	es	fisiológicamente	importante	debido	a	que	la	neutralización	de	IFN-b en ratones 
que carecen de p21 mejoran su supervivencia con la estimulación con LPS.
6. Durante la inducción de la tolerancia con LPS, p21 no afecta la actividad de NF-kB; lo que hace 
es regular el equilibrio entre su estado activo p65/p50 y su estado inhibitorio p50/p50 NF-kB, 
promoviendo la acumulación de p50/p50 que conduce a desarrollar tolerancia.
7. Encontramos	que	p21	induce	tolerancia	en	monocitos	humanos,	al	identificar	que	los	monocitos	
de pacientes sépticos presentaban una correlación negativa con respecto al IFN-b y de esta 
manera tendría importancia médica al tener una posible diana terapéutica.
94
95
REFERENCES
Abbas, T., and A. Dutta. 2009. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Can-
cer. 9:400–414. doi:10.1038/nrc2657.p21.
Adib-Conquy, M., C. Adrie, P. Moine, K. Asehnoune, C. Fitting, M. Pinsky, J. Dhainaut, and J. Cavail-
lon. 2000. NF-kappaB expression in mononuclear cells of patients with sepsis resembles that 
observed in lipopolysaccharide tolerance. Am. J. Respir. Crit. Care Med. 162:1877–83.
Afshar, R., B.D. Medoff, and A.D. Luster. 2008. Allergic asthma: a tale of many T cells. Clin. Exp. Aller-
gy. 38:1847–57. doi:10.1111/j.1365-2222.2008.03119.x.
Aita, T., M. Yamamura, M. Kawashima, A. Okamoto, M. Iwahashi, J. Yamana, and H. Makino. 2004. 
Expression of interleukin 12 receptor (IL-12R) and IL-18R on CD4+ T cells from patients with 
rheumatoid arthritis. J. Rheumatol. 31:448–56.
Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nat. Rev. Immunol. 4:499–511. 
doi:10.1038/nri1391.
Alderson, M.R., R.J. Armitage, E. Maraskovsky, T.W. Tough, E. Roux, K. Schooley, F. Ramsdell, and 
D.H. Lynch. 1993. Fas transduces activation signals in normal human T lymphocytes. J. Exp. 
Med. 178:2231–2235.
Altman,	A.,	A.N.	Theofilopoulos,	R.	Weiner,	D.H.	Katz,	and	F.J.	Dixon.	1981.	Analysis	of	T	cell	function	
in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J. Exp. 
Med. 154:791–808. doi:10.1084/jem.154.3.791.
American	College	of	Chest	Physicians/Society	of	Critical	Care	Medicine	Consensus	Conference:	defi-
nitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. 
1992. Crit. Care Med. 20:864–74.
Angus, D.C., and T. van der Poll. 2013. Severe sepsis and septic shock. N. Engl. J. Med. 369:840–51. 
doi:10.1056/NEJMra1208623.
Arias, C.F., A. Ballesteros-Tato, M.I. Garcia, J. Martin-Caballero, J.M. Flores, A.C. Martinez, and D. 
Balomenos. 2007. p21CIP1/WAF1 controls proliferation of activated/memory T cells and affects 
homeostasis and memory T cell responses. J. Immunol. 178:2296–2306. doi:178/4/2296 [pii].
Ariga, S.K., F.B. Abatepaulo, E.S.A. Melo, I.T. Velasco, F. Pinheiro da Silva, T.M. de Lima, and F.G. 
Soriano. 2014. Endotoxin tolerance drives neutrophil to infectious site. Shock. 42:168–73. 
doi:10.1097/SHK.0000000000000175.
Arsenijevic, D., H. Onuma, C. Pecqueur, S. Raimbault, B.S. Manning, B. Miroux, E. Couplan, M.C. 
Alves-Guerra, M. Goubern, R. Surwit, F. Bouillaud, D. Richard, S. Collins, and D. Ricquier. 2000. 
Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxy-
gen species production. Nat. Genet. 26:435–9. doi:10.1038/82565.
Baccala,	R.,	R.	Gonzalez-Quintial,	R.D.	Schreiber,	B.R.	Lawson,	D.H.	Kono,	and	A.N.	Theofilopoulos.	
2012.	Anti-IFN-α/β	receptor	antibody	treatment	ameliorates	disease	in	lupus-predisposed	mice.	
J. Immunol. 189:5976–84. doi:10.4049/jimmunol.1201477.
Bacon, C.M., E.F. Petricoin, J.R. Ortaldo, R.C. Rees, A.C. Larner, J.A. Johnston, and J.J. O’Shea. 
1995. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lympho-
cytes. Proc. Natl. Acad. Sci. U. S. A. 92:7307–11.
96
Baechler, E.C., F.M. Batliwalla, G. Karypis, P.M. Gaffney, W.A. Ortmann, K.J. Espe, K.B. Shark, W.J. 
Grande, K.M. Hughes, V. Kapur, P.K. Gregersen, and T.W. Behrens. 2003. Interferon-inducible 
gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. 
Acad. Sci. U. S. A. 100:2610–5. doi:10.1073/pnas.0337679100.
Bai, Y., H. Onuma, X. Bai, a. V. Medvedev, M. Misukonis, J.B. Weinberg, W. Cao, J. Robidoux, L.M. 
Floering, K.W. Daniel, and S. Collins. 2005. Persistent Nuclear Factor- B Activation in Ucp2-
/-	Mice	Leads	to	Enhanced	Nitric	Oxide	and	Inflammatory	Cytokine	Production.	J. Biol. Chem. 
280:19062–19069. doi:10.1074/jbc.M500566200.
Balomenos, D., J. Martin-Caballero, M.I. Garcia, I. Prieto, J.M. Flores, M. Serrano, and A.C. Martinez. 
2000. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. 
Nat. Med. 6:171–176. doi:10.1038/72272.
Balomenos,	D.,	R.	Rumold,	and	A.N.	Theofilopoulos.	1997.	The	proliferative	in	vivo	activities	of	lpr	
double-negative T cells and the primary role of p59fyn in their activation and expansion. J. Immu-
nol. 159:2265–2273.
Balomenos,	D.,	R.	Rumold,	and	A.N.	Theofilopoulos.	1998.	Interferon-gamma	is	required	for	lu-
pus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101:364–371. 
doi:10.1172/JCI750.
Berg, D.J., R. Kühn, K. Rajewsky, W. Müller, S. Menon, N. Davidson, G. Grünig, and D. Rennick. 
1995. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic 
shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 96:2339–47. 
doi:10.1172/JCI118290.
Beutler, B., I.W. Milsark, and A.C. Cerami. 1985. Passive immunization against cachectin/tumor ne-
crosis factor protects mice from lethal effect of endotoxin. Science. 229:869–71.
Biswas, S.K., and E. Lopez-Collazo. 2009. Endotoxin tolerance: new mechanisms, molecules and 
clinical	significance.	Trends Immunol. 30:475–87. doi:10.1016/j.it.2009.07.009.
Biswas, S.K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte sub-
sets: cancer as a paradigm. Nat. Immunol. 11:889–96. doi:10.1038/ni.1937.
Biswas, S.K., and V. Tergaonkar. 2007. Myeloid differentiation factor 88-independent Toll-like receptor 
pathway:	Sustaining	inflammation	or	promoting	tolerance?	Int. J. Biochem. Cell Biol. 39:1582–
92. doi:10.1016/j.biocel.2007.04.021.
Boehm, U., T. Klamp, M. Groot, and J.C. Howard. 1997. Cellular responses to interferon-gamma. 
Annu. Rev. Immunol. 15:749–95. doi:10.1146/annurev.immunol.15.1.749.
Bohuslav, J., V. V. Kravchenko, G.C.N. Parry, J.H. Erlich, S. Gerondakis, N. Mackman, and R.J. Ulev-
itch.	1998.	Regulation	of	an	essential	innate	immune	response	by	the	p50	subunit	of	NF-κB.	J. 
Clin. Invest. 102:1645–1652. doi:10.1172/JCI3877.
Bosque, A., J.I. Aguiló, M. del Rey, E. Paz-Artal, L.M. Allende, J. Naval, and A. Anel. 2008. Cell cycle 
regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymph-
oproliferative syndromes. J. Leukoc. Biol. 84:488–98. doi:10.1189/jlb.0108043.
Brugarolas, J., C. Chandrasekaran, J.I. Gordon, D. Beach, T. Jacks, and G.J. Hannon. 1995. 
Radiation-induced	cell	cycle	arrest	compromised	by	p21	deficiency.	Nature. 377:552–557. 
doi:10.1038/377552a0.
Bryce, P.J., C.B. Mathias, K.L. Harrison, T. Watanabe, R.S. Geha, and H.C. Oettgen. 2006. The H1 
histamine receptor regulates allergic lung responses. J. Clin. Invest. 116:1624–32. doi:10.1172/
JCI26150.
97
Bulua, A.C., A. Simon, R. Maddipati, M. Pelletier, H. Park, K.-Y. Kim, M.N. Sack, D.L. Kastner, and 
R.M.	Siegel.	2011.	Mitochondrial	reactive	oxygen	species	promote	production	of	proinflammato-
ry cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J. Exp. Med. 
208:519–33. doi:10.1084/jem.20102049.
Bygrave, A.E., K.L. Rose, J. Cortes-Hernandez, J. Warren, R.J. Rigby, H.T. Cook, M.J. Walport, T.J. 
Vyse, and M. Botto. 2004. Spontaneous autoimmunity in 129 and C57BL/6 mice-implications 
for autoimmunity described in gene-targeted mice. PLoS Biol. 2:E243. doi:10.1371/journal.
pbio.0020243.
Carmody, R.J., and Y.H. Chen. 2007. Nuclear factor-kappaB: activation and regulation during toll-like 
receptor signaling. Cell. Mol. Immunol. 4:31–41.
Carmody, R.J., Q. Ruan, S. Palmer, B. Hilliard, and Y.H. Chen. 2007. Negative regulation of toll-like 
receptor signaling by NF-kappaB p50 ubiquitination blockade. Science. 317:675–8. doi:10.1126/
science.1142953.
Carvalho-Pinto, C.E., M.I. García, M. Mellado, J.M. Rodríguez-Frade, J. Martín-Caballero, J. Flores, 
C. Martínez-A, and D. Balomenos. 2002. Autocrine production of IFN-gamma by macrophages 
controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. 
J. Immunol. 169:1058–67.
Casini, T., and P.G. Pelicci. 1999. A function of p21 during promyelocytic leukemia cell differentia-
tion independent of CDK inhibition and cell cycle arrest. Oncogene. 18:3235–43. doi:10.1038/
sj.onc.1202630.
Cavaillon, J.-M., and M. Adib-Conquy. 2006. Bench-to-bedside review: endotoxin tolerance as a mod-
el of leukocyte reprogramming in sepsis. Crit. Care. 10:233. doi:10.1186/cc5055.
Chandel, N.S., P.T. Schumacker, and R.H. Arch. 2001. Reactive oxygen species are downstream 
products of TRAF-mediated signal transduction. J. Biol. Chem. 276:42728–36. doi:10.1074/jbc.
M103074200.
Chandel, N.S., W.C. Trzyna, D.S. McClintock, and P.T. Schumacker. 2000. Role of oxidants in 
NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J. 
Immunol. 165:1013–21.
Chen, J., P.K. Jackson, M.W. Kirschner, and A. Dutta. 1995. Separate domains of p21 involved in the 
inhibition of Cdk kinase and PCNA. Nature. 374:386–8. doi:10.1038/374386a0.
Chen, W., Z. Sun, X.-J. Wang, T. Jiang, Z. Huang, D. Fang, and D.D. Zhang. 2009. Direct Interaction 
between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response. Mol. 
Cell. 34:663–673. doi:10.1016/j.molcel.2009.04.029.
Cheng, T., N. Rodrigues, H. Shen, Y. Yang, D. Dombkowski, M. Sykes, and D.T. Scadden. 2000. He-
matopoietic stem cell quiescence maintained by p21cip1/waf1. Science. 287:1804–8.
Child, E.S., and D.J. Mann. 2006. The intricacies of p21 phosphorylation: protein/protein interactions, 
subcellular localization and stability. Cell Cycle. 5:1313–9.
Coqueret, O. 2003. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compart-
ment?	Trends Cell Biol. 13:65–70.
Cubillos-Zapata, C., E. Hernández-Jiménez, V. Toledano, L. Esteban-Burgos, I. Fernández-Ruíz, V. 
Gómez-Piña, C. Del Fresno, M. Siliceo, P. Prieto-Chinchiña, R. Pérez de Diego, L. Boscá, M. 
Fresno,	F.	Arnalich,	and	E.	López-Collazo.	2014.	NFκB2/p100	is	a	key	factor	for	endotoxin	toler-
ance in human monocytes: a demonstration using primary human monocytes from patients with 
sepsis. J. Immunol. 193:4195–202. doi:10.4049/jimmunol.1400721.
98
Dasgupta, P., and A.D. Keegan. 2012. Contribution of alternatively activated macrophages to allergic 
lung	inflammation:	a	tale	of	mice	and	men.	J. Innate Immun. 4:478–88. doi:10.1159/000336025.
Daszkiewicz, L., C. Vázquez-Mateo, G. Rackov, A. Ballesteros-Tato, K. Weber, A. Madrigal-Avilés, 
M. Di Pilato, A. Fotedar, R. Fotedar, J.M. Flores, M. Esteban, C. Martínez-A, and D. Balomenos. 
2015a.	Distinct	p21	requirements	for	regulating	normal	and	self-reactive	T	cells	through	IFN-γ	
production. Sci. Rep. 5:7691. doi:10.1038/srep07691.
Dejager, L., S. Vandevyver, M. Ballegeer, E. Van Wonterghem, L.-L. An, J. Riggs, R. Kolbeck, and 
C. Libert. 2013. Pharmacological Inhibition of Type I Interferon Signaling Protects Mice Against 
Lethal Sepsis. J. Infect. Dis. 209:960–970. doi:10.1093/infdis/jit600.
Delavaine, L., and N.B. La Thangue. 1999. Control of E2F activity by p21Waf1/Cip1. Oncogene. 
18:5381–92. doi:10.1038/sj.onc.1202923.
Del Fresno, C., F. García-Rio, V. Gómez-Piña, A. Soares-Schanoski, I. Fernández-Ruíz, T. Jurado, 
T. Kajiji, C. Shu, E. Marín, A. Gutierrez del Arroyo, C. Prados, F. Arnalich, P. Fuentes-Prior, S.K. 
Biswas, S.K. Biswas, and E. López-Collazo. 2009. Potent phagocytic activity with impaired 
antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in 
isolated	monocytes	from	cystic	fibrosis	patients.	J. Immunol. 182:6494–507. doi:10.4049/jimmu-
nol.0803350.
Del Fresno, C., V. Gómez-Piña, V. Lores, A. Soares-Schanoski, I. Fernández-Ruiz, B. Rojo, R. Alva-
rez-Sala, E. Caballero-Garrido, F. García, T. Veliz, F. Arnalich, P. Fuentes-Prior, F. García-Río, 
and	E.	López-Collazo.	2008.	Monocytes	from	cystic	fibrosis	patients	are	locked	in	an	LPS	toler-
ance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS One. 3:e2667. 
doi:10.1371/journal.pone.0002667.
Del Fresno, C., K. Otero, L. Gomez-Garcia, M.C. Gonzalez-Leon, L. Soler-Ranger, P. Fuentes-Prior, 
P. Escoll, R. Baos, L. Caveda, F. Garcia, F. Arnalich, and E. Lopez-Collazo. 2005. Tumor Cells 
Deactivate Human Monocytes by Up-Regulating IL-1 Receptor Associated Kinase-M Expression 
via CD44 and TLR4. J. Immunol. 174:3032–3040. doi:10.4049/jimmunol.174.5.3032.
Deng, C., P. Zhang, J.W. Harper, S.J. Elledge, and P. Leder. 1995. Mice lacking p21CIP1/WAF1 
undergo normal development, but are defective in G1 checkpoint control. Cell. 82:675–684. 
doi:0092-8674(95)90039-X [pii].
Di Cunto, F., G. Topley, E. Calautti, J. Hsiao, L. Ong, P.K. Seth, and G.P. Dotto. 1998. Inhibitory func-
tion of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle 
control. Science. 280:1069–72.
Döcke, W.D., F. Randow, U. Syrbe, D. Krausch, K. Asadullah, P. Reinke, H.D. Volk, and W. Kox. 1997. 
Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3:678–
681. doi:10.1038/nm0697-678.
Dotto,	G.P.	2000.	p21(WAF1/Cip1):	more	than	a	break	to	the	cell	cycle?	Biochim. Biophys. Acta. 
1471:M43–56.
Edwards, J.P., X. Zhang, K.A. Frauwirth, and D.M. Mosser. 2006. Biochemical and functional 
characterization of three activated macrophage populations. J. Leukoc. Biol. 80:1298–1307. 
doi:10.1189/jlb.0406249.1.
El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, 
K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. 
Cell. 75:817–25.
Elkon, K.B., and V. V Stone. 2011. Type I interferon and systemic lupus erythematosus. J. Interferon 
Cytokine Res. 31:803–12. doi:10.1089/jir.2011.0045.
99
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